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In malignant tumor cells, it is observed that increasing in glucose catabolism 
occur frequently in order to obtain extra energy for their growth. This overall extra 
energy demand in malignant cells may be met by increased expression of glucose 
transporters (Glut). There are six types of glucose transporters (Glut 1-5 and Glut?). 
Tumor cells exhibit increased expression of glucose transporters, namely Glut 1. 
Specifically, colorectal cancer involves over-expression of GlutS. Glut5 facilitative 
transporter is also responsible for the absorption of fructose, one of the major dietary 
sugars, from the intestinal lumen. Caco-2 is a colon adenocarcinoma cell line, which 
over-expresses Glut5. This cell line was used as an in vitro model to examine the 
antitumor effect of antisense oligonucleotide against GlutS in this study. 
Antisense oligonucleotides complementary to specific mRNA sequence are 
widely used as inhibitors of gene expression in vitro and in vivo. In this study, the 
effects of antisense oligonucleotides against Glut5 gene in Caco-2 cells were tested. 
In in vitro study, the uptake of phosphorothioate antisense oligonucleotide was 
enhanced by Lipofectin. By flow cytometry, the amount of antisense 
oligonucleotide uptake in different culture conditions was monitored by FITC-
phosphorothioate antisense oligonucleotides. The effects of transfection time, -
oligonucleotide length, and oligonucleotide and Lipofectin ratio were studied, and 
thus the optimizing conditions for oligonucleotides uptake could be worked out. On 
i designing the antisense oligonucleotides against GlutS, it is found that 15-mer 
antisense oligonucleotide targeting the AUG start codon of the Glut5 gene, namely 
— G5 7015 was most effective in giving antitumor effect than other four antisense ‘ 
oligonucleotides flanking other regions of Glut5 gene. Proliferation and cells 
i . [ 
I - ii -
viability were examined by [^H]-thymidine incorporation and MTT assay, 
respectively. Tumor cell growth was inhibited by about 60% as determined by an 
MTT assay at concentration of 10)iM and similarly, the cell growth was inhibited by 
about 50% as determined by [^H]-thymidine incorporation at concentration of 8)aM. 
1 
I In contrast, treatment with scrambled control or sense control oligonucleotides did not 
significantly inhibit Caco-2 cell growth i f the oligonucleotide and Lipofectin ratio was 
1:1. Levels of Glut5 mRNA expression were determined using semi-quantitative 
I 
RT-PCR, and Glut5 protein synthesis was evaluated with Western blotting and 
fmctose uptake. Marked inhibition of Glut5 mRNA expression was observed. 
丨i 
!i 
I Dose (0 to Sj^M) and time dependent (0-48 hours post-incubation in complete 
j medium) effects on decreases in mRNA level, Glut5 activity and cells proliferation 
were observed in Caco-2 cells after G5 7015 treatment. Antisense effect began to 
I 
recover at 72 hours post-incubation. Inhibition of cell growth may be due to the 
inhibition of ATP content of Caco-2 cells. 
In 
in vivo study, the effect of G5 7015 was examined using subcutaneously 
implanted Caco-2 cells in nude mice. Tumor-bearing mice received intravenous 
I injections at alternate day for 20 days (i.e. ten doses) at concentration of 
i i 
4mg/kg/injection. The mRNA levels of Glut5 in the tumor cells were significantly 
i 
1 
reduced comparing with those of sense and saline control. 
i 
I i 
I Besides，the relationship between glucose transport and multi-drug resistance 
I 
(MDR) in human tumor cells using human hepatoma cell (HepG2) as an example has 
been examined. The development of multidrug resistance in tumor cells is often 
associated with the increase expression of an ATP dependent drug efflux pump, P-
glycoprotein (P-gp). The possible roles for the glucose transporter in modulation of 







resistant cell line, namely HepG2 with MDR (R-HepG2) comparing to parental cell 
j line was found. However, the levels of Glut 1 and Glut 3 facilitative transporters 
1 were found to be reduced in the MDR cell lines by RT-PCR. It was also found that 
glucose transporter inhibitor, phloretin and cytochalasin B or mitochondrial inhibitor, 
2,4-Dinitrophenol could increase the doxorubicin accumulation in MDR cells as 
measured by flow cytometry. On the same time, antisense oligonucleotide against 
I Glut 1 could also increase the doxorubicin accumulation in MDR cells. 
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I 論文撮耍 
在惡性的癌細胞中，葡萄糖的分解作用通常會增加，從而獲得額外的能量 
應付癌細胞的生長，這些能量可能是來自增加葡萄糖轉運蛋白（G l u c o s e 
transporter)的表達而獲得。事實上，葡萄糖轉運蛋白可分爲六大類〔葡萄糖轉 



















比色法（MTT assay)測定。由MTT比色法得知，如加入 lOj iM的反義寡核甘 
酸片段，可達到的最大的細胞存活的抑制率爲60%，而 3 H-胸腺嚼淀核甘滲入 
法實驗亦有相似發現，如加入8 ^ iM的反義寡核甘酸片段，可達到的最大的細 
胞增殖的抑制率爲50% 0相反地，正義寡核甘酸片段控制實驗（Sense control 
oligonucleotide ) 及 雜 亂 寡 核 甘 酸 片 段 控 制 實 驗 （ S c r a m b l e d control 
oligonucleotide)則不會影響Caco2細胞生長。葡萄糖轉運蛋白五型的信使核糖 
核酸（mRNA)表達由逆轉錄-聚合酶鏈式反應法（RT-PCR)測定，而蛋白的 
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的葡萄糖吸收量比母細胞爲多，但是，逆轉錄-聚启@每鏈式反應法顯示萄糖轉 
運蛋白一型及萄糖轉運蛋白三型的mRNA表達降低了。利用細胞流式分析法， 
實驗亦發現萄糖轉運蛋白抑制劑（G l u c o s e transproter inhibitor )：根皮素 
(Phloretin)及細胞鬆弛素（Cytochalasin B)或粒腺體抑制劑：2，4 —二硝酸苯 
m (2,4-Ditrophenol)能增加細胞內阿霉素。同時，控制葡萄糖轉運蛋白一型的 
反義寡核甘酸片段也能增加多藥抗藥性細胞內阿霉素。 
J - vii -
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Chapter 1 Introduction 
CHAPTER 1 
INTRODUCTION 
1.1 Facilitative glucose transporters 
Glucose transporters are membrane proteins that transport sugar such as glucose, 
galactose and fructose. These sugars are predominant sources of energy utilized by 
mammalian cells. The majority of cells acquire this resource via protein-dependent 
movement of glucose across the plasma membrane. A family of proteins has been 
identified to be responsible for this process and there are two types of glucose 
transporters, Na+-dependent active glucose transporter (SGLT family) and facilitated-
difflision glucose transporter (Glut family) are known to exist in mammalian cells. 
Seven types of glucose transporter isoforms have been cloned to date namely Glut 1-5 
and Glut?. Glut6 is a pseudogene that is not expressed at the protein level (Mueckler, 
1994). 
1-1.1 Predicted Secondary structure of Glutl 
Hydropathy analysis of the primary structure of Glutl suggests the formation of 12 
membrane-spanning a-helices. Five of these are predicted to be amphipathic-helices 
3,5，7，8 and 11 and could form hydrophilic binding regions through the membrane bilayer 
allowing the passage of D-glucose (Figure 1.1.1). The hydropathy analyses of 
subsequently cloned transporter display identical patterns. The amino acid sequences 
of the putative transmembrane helices are more highly conserved than those of the 
—extramembranous loops. The two largest loops and N and C termini are least conserved _ 
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Figure 1.1.1 Schematic arrangement of the 12 membrane-spanning domain 
structure of the Gluts (Gould and Bell, 1990). 
Residues conserved between Gluts 1-5 are indicated by single-letter codes. Darker 
regions have been predicted to be important functional domains for Glutl. 
t 
i 1.1.2 The tissue-specific distribution of glucose transporters 
i 
Members of the Glut family exhibit tissue-specific pattern of expression, which can 
be explained in part on the basis of their functional properties. Some major features of 
— Glut proteins are summarized in Table 1 (Mueckler, 1994). 
1 
- - 2 -•-C : % 
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Chapter 1 Introduction 
tissues; abundant m human growing or dividing cells; transport across 
red cells, endothelial, and blood brain barrier 
many cell lines 
cells, intestine and kidney 
^ ^ “ ^ ^ Basal transport in many human cells; 
uptake from cerebral fluid into brain 
parenchymal cells 
adipocytes elevated blood insulin; important in whole 
body glucose disposal 
Glut 7 May be a cloning artifact 
Table 1. Some major features of Glut proteins 
Glu t l is a widely expressed isoform that provides many cells with the basal glucose 
requkement. In human it is expressed at highest levels in brain and erythrocytes, but is 
also enriched in cells of the blood-tissue barriers such as the blood-brain/nerve barrier, 
the placenta and the retina (Calderhead and Lienhard, 1988; Farrell and Pardridge, 1991). 
Glutl protein is low level in muscle and fat, but these tissues express 腿c h higher levels 
of Glut4. In the liver Glutl is also found at very low level, which has high levels of 
Glut2. Hence, the tissues responsible for maintaining whole-body glucose homeostasis 
all contain high levels of transporter isoforms other than Glutl. 
- 3 -
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Glut 2 is a high-Km isoform expressed in hepatocytes, pancreatic-p cell and 
basolateral membrane of intestinal. 
Glut 3 is a low-Km isoform responsible for glucose uptake into neuron. GlutS 
protein expression levels are highest in brain and neural tissue. In brain, under normal 
conditions the capacity of hexokinase for glucose is considerably greater than the 
capacity of the glucose transport systems in this tissue. However, under conditions 
either of high glucose demand or hypoglycemia, the expression of transporter in the 
brain with a low K^ for glucose may be required to utilize efficiently low concentrations 
of blood glucose. 
Glut 4 is expressed exclusively in the insulin-sensitive tissues, fat and muscle. 
The feature of Glut4 is that in absence of insulin, this transporter is sequestered into a 
subcellular compartment. In brown adipocytes, for example, less than 2% of the total 
cellular Glut4 is present at the cell surface. In response to insulin, there is a rapid and 
large mobilization of the sequestered transporter to the plasma membrane, resulting in 
large increases in the number of functional Glut4 molecules at the surface. (Slot et al.， 
1991). Defects in this translocation event are proposed to cause insulin resistance 
(Kahn, 1992). 
Glut 5 is fructose transporter that is abundant in spermatozoa and the apical 
j membrane of intestinal cells (Burant and Bell 1992). Expression-of human Glut5 
f 
i cDNA 
in oocytes revealed that the protein was incapable of measurable glucose transport, 
I but was found instead to be a high affinity D-fructose transporter (Km- 6mM) (Kane et 
I 
‘ al” 1997) Glut2 and GlutS together are responsible for the transporter ofhexose. Figure 
I r 
‘ 1.1.2 suggests the possible mechanism of hexose transport epithelia of the small 
I intestine. “ 
I -
1： I , ；^  i 
- 4 -
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Figure 1.1.2 Schematic model of the hexose transporter present in 
absorptive epithelia of small intestine (Scatter and Gould, 
1999). 
Glut 7 seems to be a cloning artifact discovery in recent year (Burchell, 1998). 
1.2 Increase of glucose uptake in cancer cells 
The increase of glucose uptake is a characteristic of cancer cells. This 
phenomenon has attracted increasing interest as an adjunct to clinical protocols, for 
example, 18-deoxyglucose (FDG)，a glucose analogue, has been widely used for tumor 
imaging (Crespi et al, 1999; Pauwels et al, 1998). Glucose transporters in cancer cells 
mediate the acceleration of glucose uptake. Many tumors over-express glucose 
- 5 -
i 
Chapter 1 Introduction 
transporter isoforms. Various human cancers over-express Glutl including colorectal 
carcinoma (Haber et al., 1998)，head and neck tumor (Reisser et al.，1999)，or breast 
cancer (Crespi et a l , 1999). Glut 2 is over-expressed in hepatic tumor (Grobholz et al., 
1993). Gluts is over-expressed in lung cancer and their liver metastases (Kurata et al., 
1999), gastric tumors (Noguchi et al., 1999) or ovarian carcinomas (Younes et al., 1997). 
Glut4 is expressed in gastric tumors (Noguchi et al., 1999). Glut5 is over-expressed in 
colon cancer (Mesonero et al., 1995). 
Glut 5 is a fructose transporter, which transports fructose and is expressed in the 
small intestine, kidney and testis in human (Burant et a l , 1992). In the small intestine, 
Glut 5 is present in the absorptive epithelial cell, which is localized along the apical 
brush borders (Davidson et al., 1992). It is proposed that GlutS plays an important role 
in the uptake of fructose from the intestinal lumen. Fructose is a monosaccharide 
commonly found in food and intestinal hydrolysis products. Thus, it may affect the 
proliferation of cancer cells. Caco-2 cell, a human colon adenocarcinoma cell line, 
expresses several types of glucose transporters including SGLTl，Glutl (Mahraoui et al., 
I 1994), Glut2 (Brot-Laroche, 1996), GlutS (Harris et al., 1992)，and Glut5 (Mahraoui et 
1 
; al.，1992; Mesonero et al., 1995). This cell line wi l l be used to study whether the 
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1.3 Antisense oligonucleotide therapeutics 
The use of antisense oligonucleotide (OND) as both research tools and therapeutic 
molecules has been growing out at a very rapid rate over the past decade since their first 
proposed use in 1978 by Zamecnik (Zamecnik and Stephenson, 1978). The central idea, 
that antisense oligonucleotide are short pieces of synthetic, chemically modified DNA 
designed to hybridize to specific mRNA sequences via Watson-Crick base pairing. 
Statistically, the minimum number of nucleotides that occurs just once in human genome 
is, on average 13. Thus, antisense oligonucleotide longer than this should be able to 
bind selectively to unique RNA species in the cell. Upon binding to the mRNA in the 
cell，the antisense oligonucleotide prevents expression of product encoded by the target 
RNA (Crooke, 2000; Bennett, 1998; Cooper et a l , 1999). In order to use antisense 
oligonucleotide in research, design of oligonucleotide, the action mechanism and cellular 
uptake of oligonucleotide in in vitro experiment must be well known. It fact, antisense 
therapy is now applied in human studies. 
1.3.1 Chemical modifications of oligonucleotides 
Unmodified, natural oligonucleotides are rapidly degraded in the cellular 
environment due to the action of nucleases that hydrolyze the phosphodiester (PO) bond. 
As a consequence, considerable effort has focused on the synthesis of oligonucleotides 
[ having modification that make oligonucleotide nuclease resistant (Figure 1.3.1), but it is 
still able to form stable duplexes with RNA target and consequently suppress translation 
I i 
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Figure 1.3.1 Oligonucleotide modifications 
(I) Backbone Modifications 
Attempts to generate antisense oligonucleotides with improved nuclease resistance 
were initially focused on modification of the PO part of deoxyribose-phosphate 
backbone and have been referred to as "first generation backbone modifications". This 
type of modification involved the replacement of one of the nonbridging oxygen atoms 
of the moiety by sulfur (phosphorothioates [PS], 1)，a methyl group (methylphosphonates 
2) or by various amines (phosphoramidates 3) (Figure 1.3.1.2 ). 
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Figure 1.3.1.2 First generation backbone modifications in antisense 
oligonucleotides: replacement of the PO linkage by (1) 
phosphorothioate, (2) methylphosphoate, or (3) 
phosphoramidate. 
Phosphorothioates 
The most commonly used and widely commercially available chemically modified 
oligonucleotides are phosphorothioate (P=S) oligodeoxynucleotides. In this 
modification, the oxygen atoms in the phosphate group are replaced by sulfur. This 
modification resulting compound is negatively charged and clearly achieves the 
objective of increased nuclease stability (Ghosh et al., 1993). These phosphorothioate 
oligonucleotides have greater stability in biological fluids than normal oligonucleotides. 
Phosphorothioate oligonucleotides are degraded slowly by cells in tissue culture with a 
half-life of 12-24 hours and are metabolized slowly in animals (Crooke, 2000). This 
type of modification will be selected in my experiments. 
(II) Sugar Modifications 
A wide variety of sugar modifications have been introduced into antisense 
oligonucleotides to enhance their nuclease stability. Substitutions and alterations of 
every positions of ribose sugar have been studied including 2, sugar modification (Figure 
1.4.3.3, 1-3), and a number of other ribose positions have been modified (Figure 1.4.3.3, 
- 9 -
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7-12) or even replacement of the ribose sugars by hexoses (13). 2' sugar modifications 
is one of the common modifications, it modified C, position of the sugar (ribose) of 
oligonucleotide include 2 ‘ -fluororibonucleotides and resulted in productions of 2，-0-
methoxyethylribonucleotides (2，-MOE,4)，2'-allylribonucleotides(2‘-0-allyl, 5), or 2'-
Fluoro substitution (6). These modifications are summarized in Figure 1.3.1.3. 
V W X Y Z R , m o d i f i c a t i o n s 
4 O H H H H 0 1 ^ 2,-0-methyl 
5 O H H H H OAllyl 2'-0-alkyl 
6 O H H H H F 2'-fluororibose 
7 O CH3 H H H H 1'-methyl 
8 O H CH2OH H H H 3'-hydroxymethyl 
9 O H H CH2OH H H 4'-hydroxymethyl 
10 O H H H CH3 H 5'-methyl 
11 CH2 H H H H H Carbocyclic nucleotides 
12 S H H H H H 4'-thioribonucleotides 
\ A 
o , 八 O Z 
6 
〇 R1 \ — 
Figure 1.3.1.3 Summarized of sugar modifications. 
( I l l ) Peptide nucleic acid (PNA) analogs 
- Peptide nucleic acids constitute one of the most radically different oligonucleotide 
analogs (Figure 1.4.1.4)，as the entire ribose-PO backbone is replaced by peptide 
- 1 0 -
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backbone. An oligonucleotide analog that incorporates features of both DNA and PNA 
is the novel phosphorester nucleic acid (PHONA). This analog contains a backbone 
that resembles both the PO of natural DNA as well as PNA. PHONA exhibit good 
water solubility and promising binding properties to nucleic acid target (Nielsen, 2000). 
〇 n " 
I 厂 〇 \ /O -
HO / f 〇、pC^ ^ O H 
3 . - 《 t V 5.-
T d G A 
II II 
A G (W T 0 0 0 0 
n ^ n ^ n CARBOXY 
AMINO 了 U 了 U [ ^ 
2 H H H 
Figure 1.3.1.4 An antiparallel PNA-DNA duplex showing the chemical 
structure of PNA (lower strand) as compared to that of DNA 
(upper strand). 
1.3.2 Cellular Uptake of Oligonucleotide 
Enhancers which are used to increase oligonucleotide intracellular accumulation in 
vitro including cationic lipid (Marcusson et al., 1998)，liposomes (Lubrich et al., 2000), 
peptides (Bongartz et al” 1994), dendrimers (Kukowska-Latallo et a l , 1996), polycations 
(Boussifet al , 1995)，conjugation with cholesterol (Alahari et al.，1996), aggregtion with 
cell surface ligands (Duff et al, 2000), streptolysin 〇 (Gi les et al , 1998) and 
electroporation (Bergan et al.，1993). One of the most commonly used enhancers is a 
mixture of a neutral lipid with a cationic lipid. For example, a cationic lipid reagent 
transfection applicatins is available commercially under trade name Lipofectin Reagent 
as a l : l (w/w) liposome formulation of the cationic lipid N-(l-(2,3-dioleoyloxy)propyl)-




Chapter 1 Introduction 
N,N,N-trimethylammonium cloride (DOTMA) and fusion-enhancing neutral lipid 
dioleoyl phosphatidyl-ethanolamine (DOPE). The cationic lipid is the more crucial part 
of the neutral lipid and cationic lipid mixture, as cationic lipids alone enhance antisense 
oligonucleotide activity, whereas neutral lipids cannot. The mechanism by which 
cationic lipids increase the activity of antisense oligonucleotides is poorly understood, 
but presumably involves a transient destabilization of endosomal membrane or the 
plasma membrane. The lipid bilayer of the endosomal membrane would normally be 
very impermeable towards charged oligonucleotides. However, upon entering the 
endosome, the cationic lipid complex recruits anionic phospholipids found on the 
cytoplasmic face of the endosome bilayer, thus probably inducing a transition to a non-
bilayer state (Zelphati and Szoka, 1996). Figure 1.3.2 shows some of the structure of 
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Figure 1.3.2 Examples of cationic lipids 
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1.3.3 Mechanism of action 
Once the oligonucleotide binds to the target mRNA, there are several possible 
processes that can result in inhibition of expression of the encoded protien. The action 
mechanism of antisense oligonucleotide be can divided into two main categories, (A) 
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Figure 1.3.3 Potential sites of action for antisense based drugs. 
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Antisense-mediated RNA Cleavage 
Antisense-mediated cleavage of RNA is also a very common mechanism for 
inhibiting RNA function. Unlike non-cleaving mechanism, this mechanism induce 
cleavage and degradation of target RNA by antisense oligonucleotide. 
(i) Activation of RNase H 
RNase H is an ubiquitous enzyme that degrades the RNA strand of an RNA-
DNA duplex. This family of endonucleases cleaves the RNA, producing 5'phosphate 
and 3，hydroxy termini. The resulting cleavage products lack a 5'cap and 3, 
polyadenylation and thus results in degradation of mRNA and 5, and 3, exonucleases.. 
The oligonucleotide is not destroyed by RNaseH and thus can survive to anneal to a new 
target mRNA transcript. In this way, one antisense oligonucleotide can mediate the 
RNase H dependent cleavage of many target mRNA molecules (Lledo et al., 2000). 
In fact, RNase H is a commonly used termininating mechanism for antisense 
treatment. Firstly, RNase H enzymes are present in most mammalian cells, and RNase 
H does not appear to be a rate-limiting reaction in cells. Secondly, phosphorothioate 
oligonucleotides serve as efficient substrates (when duplexed with RNA) for RNase H 
— enzymes. This is important because the vast majority of backbone or sugar 
modification of oligonucleotides are incapable of activating RNase H. As 
phosphorothioate oligonucleotide is commonly used and thus many applied antisense 
oligonucleotides were designed to activate RNase H. 
RNase H-independent RNA cleaving mechanism RNase P, RNase or double 
stranded RNase can also degradate antisense:RNA duplex. 
- 1 4 -
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"Occupancy-only" mediated mechanism 
Antisense oligonucleotide theoretically is possible to modulate RNA function with 
antisense by hybridization to specific RNA sequences to prevent the binding of 
important regulatory protein and may result in modulation of RNA splicing, translation 
arrest or disruption of necessary RNA structure. This type of responses would typically 
rely on a non-RNA cleaving mechanism of action, thus named "occupancy only" (Baker 
and Monia, 1999). 
(i) Translational Arrest 
This is the physical block of the translation by binding of the initiation complex 
(40S subunit) at the AUG initiation codon or at the region that covers the ribosome 
binding site, upstream of the initiation (close to the cap region, Figure 1.4.4.1) 
5 丨 AUG STOP 3 丨 
CAT - -
For examples, 2'-0-methyl-modified oligonucleotides (2'-0-methoxyribonucleotides) 
targeted to the initiation of protein synthesis of Intercellular adhesion molecule 1 
(ICAM-1), but did not change the level of ICAM-1 mRNA (Chiang et al., 1991). 
Another way resulted in translation arrest is targeted 5'-cap of ICAM-1 and inhibition of 
protein expression by RNase H independent mechanism or splicing or transport of the 
ICAM-1 transcript, but instead to selective interference with the formation of the 80 S 
translation initiation complex (Baker et al., 1997). 
- 1 5 -
i 
Chapter 1 Introduction 
(ii) Inhibition of Splicing 
A key step in the intermediary metabolism of most mRNA molecules is the excision 
of introns. Consequently, oligonucleotides that bind to the sequences required for 
splicing may prevent the binding of necessary factors or physically prevent the required 
cleavage reaction. Thus, result in inhibition of the production of the mature mRNA 
(Sierakowska et al.，2000). For example, using a 14 mer 2'-0me oligonucleotide that 
can correct aberrant (3-globin splicing of human P-globin gene. Patient with a mutation 
((3 110) at position 110 (T to G) within intron 1 wi l l results in the creation of an aberrant 
3’ splicing site. 2'-0me oligonucleotide can correct splicing and produce functional 
protein. 
(iii) Disruption of Necessary RNA structure 
RNA adopts a variety of three dimensional structure induced by intramolecular 
hybridization, the most common of which is the stem loop. Oligonucleotides that bind 
to the important stem loop can disrupt RNA 
(iv) 5'-Capping 
A Key early step in RNA processing is 5'-capping. This stabilizes pre-mRNA and 
is important for stability of mature mRNA. Several oligonucleotides that bind near the 
cap site have been shown to be active, presumably by inhibiting the binding of proteins 
required to cap the RNA. 
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1.3.4 Antisense treatment in vivo 
Oligonucleotide uptake in animals seems to involve different mechanism than 
uptake in tissue culture. For example, uptake enhancers is often not needed in animal 
experiments. Again phosphorothioate oligonucleotides were commonly used in vivo 
experiments. After intravenous injection, phosphorothioate oligonucleotide was 
distributed rapidly to peripheral tissues with the majority going to the kidney and liver 
but significant accumulation also occurs in bone marrow, spleen, heart and gut. 
However, very little oligonucleotide enter the brain (Raynaud et al., 1997). 
Nevertheless, oligonucleotide wil l undergo degradation in the liver 6-8 hours after i.v. 
administration. The plasma half-life of elimination was about 22 hours (Graham et al., 
1998). Safety studies of phosphorothioate oligonucleotide in mice and rats show 
sequence-dependent side effects. A major side effect is stimulation of immune system 
that involves lymphoid hyperplasia, splenomegaly and mononuclear cell infiltration into 
several The splenomegaly involves a polyclonal B cell activation that appears to be a 
mitogenic response to CG and other motifs present in the oligomer (Agrawal, 1999). 
The safety of phosphorothioate oligonucleotide in monkeys is different from that 
observed in mice and rats. Intravenous administration of phosphorothioate 
oligonucleotide in monkeys caused a brief increase, followed by a prolonged decrease, in 
arterial blood pressure, and a transient decrease in peripheral total white blood cells and 
neutrophil counts. 
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1.4.5 Human Studies of Antisense Treatment 
In fact, a number of reports have demonstrated antisense on cancer-related 
[ genes both in cell culture and in tumor or human tumor xenograft models. Twelve 
； antisense compounds, all with phosphorothioate backbones, have been currently 
investigated in clinics (Table 1.3.5). Six were in development for cancer, [c-myb 
j (Gewirtz, 1999)，bcl-2 (Webb et al., 1997), PKA (Wang et al.，1999), PKC-a (Yuen et al., 
! 
t 
！ 1999), c-raf kinase (O'Dwyer et al, 1999), and Ha-ras antisense], four for viral infection 
{cytomega lovius [CMV], human immunodeficiency virus [HIV] (Marwick, 1998; Gee 
t 
I et al, 1998)}. One targets c-myc for the prevention of smooth-muscle proliferation and 
1 
！ restenosis following balloon angioplasty, and one, targeting intercellular adhesion 
I 
molecule-1 (ICAM-1), is in development for spectrum of inflammatory diseases 
I (Yacyshyn et al., 1998). Recently, the Food and Drug Adminstration issued approval 





f ； Target Indication Phase No. of I： 
I nucleotides 
I c-myc (LR-3280) Restenosis i 18 
I 
I c-myb (LR-3001) Leukemias (CML and ALM) 1 24 
I PKA (GEM 231) Solid tumors i fg 
I - Bcl-2 (G3139) Recurrent non-Hodgkin's 1 ^ 
lymphoma 
PKC-a (ISIS 3521) Solid tumors (pancreas, colon, 2 ^ 
stomach, lung and ovarian) 
I 
J c-raf kinase (ISIS 5132) Solid tumors (colon, ovarian, 2 ^ 
m： 
j pancreatic, renal cell tumor) — 
I ： I Cytomegalovirus CMV retinitis 1 ^ 
d "“. I • • — I 
-
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： Cytomegalovirus CMV retinitis/systemic 2 
\ (GEM 132) 
i 
t Cytomegalovirus CMV retinitis 3NDA filed 
i (ISIS 2292)/fomivirsen 
HIV (GEM 92) HIV 1 Yl 
ICAM-1 (ISIS 2 3 0 2 ) C r o h n ' s disease, ulcerative 2 ^ 
colitis, rheumatoid arthritis, 
I 
t renal transplantation 
I Table 1.3.5 Antisense Oligonucleotides in Clinical Trials 
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CHAPTER 2 
MATERIALS & METHODS 
2.1 Materials 
Roswell Park Memorial Institute tissue culture medium 1640 (RPMI 1640 medium) 
The powder from packages of RPMI 1640 medium were purchased from GIBCO-BRL. 
Each pack containing phenol red, L-glutamine and O.SmM HEPES was dissolved in IL 
of distilled H2O. 2g at weight of NaHCO; was supplemented to the medium. The pH 
of the medium was adjusted to pH at 7.1-7.4. Medium was filtered by 0.22j^m bottle-
top filter to ensure it was sterized . Cells were cultured with complete medium which 
contained 5ml penicillin-streptomycin (10,000units/ml) (GIBCO-BRL) and 10% (v/v) 
Bovin serum albumin (GIBCO-BRL). Medium were stored at at 4。C. 
Phosphate Buffer saline (PBS) 
136mM NaCl，2.7mMKCl, 1.5mM KH2PO4 and 8mM Na^PO* were mixed and adjusted 
the pH to 7.4. It was sterized by autoclave and stored at 4。C 
3-(4,5-dimethyldiazol-2-yl)-2.5-diphenyltetrazolium bromide (MTT) 
It was purchased from Sigma and was dissolved in PBS to give a final concentration of 
5mg/ml and filtered with a 0.22jam millipore filter. 
- 2 0 -
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2.2 Cell Culture 
2.2.1 Human colon adenocarcinoma cell Line (CacO'2) 
The human colon carcinoma cell line, Caco-2 was obtained from American type Culture 
Collection (ATCC, Roctvile, MD, USA). According to producer, this cell line was 
human colon adenocarcinoma from an 72 years old male. Cells were maintained as 
monolayer culture at 37。C in a humidified atmospere of 5% CO:，95% air in RPMI 1640 
medium (GIBCO-BRL) containing 10% fetal bovin serum (GIBCO-BRL) and 1% 
penicillin-streptomycin (lOOU/ml) (GIBCO-BRL). Caco-2 cells were routinely 
subcultured once a week and seeded at a density of 5x10^ cells per flask (75cm^). 
When the cells reach confluence, cells were washed twice with PBS. Then cells were 
trypsinized with 1ml trypsin-EDTA (0.25%，ImM) (GIBCO-BRL) by incubated at 37°C 
for 5 minutes. Complete medium was then added to resuspense the cells. 
- 2 1 -
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2.3 General Methodology for treatment of cells with 
antisense oligonucleotides 
2.3.1 Treatment of cells with oligonucleotides 
Lipofectin reagent (GIBCO-BRL) and oligonucleotides were each diluted separately 
into RPMI 1640 medium without serum or antibiotics and incubate for 45 minutes at 
room temperature. The diluted oligonucleotides and cationic lipid were combined, 
mixed gently, and further incubated for 15 minutes at room temperature to allow the 
formation of cationic lipid/oligonucleotide complexes. 
Cells were seeded on plates or wells by complete medium to allow the cells 
adherent for overnight (15-24 hours) at about 40% confluence. Then the medium was 
discarded and the cells were washed twice with serum-free, antibiotic-free RPMI 1640. 
The cationic lipid/oligonucleotide complex solution was added to cells. Cells were 
incubated with various concentrations of oligonucleotide in serum-free medium 
containing varying amounts of cationic lipid for 24 hours at 37。C with 5% C0\ Then, 
the cationic/oligonucleotide complex solution was removed from cells. The cells were 
washed twice with complete medium. Cells were further incubated in RPMI 1640 with 
I 10% serum for 24-72 hours. Assays were performed at that time. 
j FuGENE6 (Boehringer Mannheim) was diluted with serum, and antibiotic free 
[• -
i medium and incubated for 5 minutes at room temperature. The same amount of 
oligonucleoitde was added into the prepared transfection reagent FuGENE6. The 
mixture was incubated for 15 minutes at room temperature to form complex before 
adding to cells. 
I 
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2.4 Cytotoxicity Assay 
2.4.1 MTT assay 
lx l04 cells were seeded on 96 well plates. After treatments, the medium in each 
wells were discarded and 50}il of MTT solution (5mg/ml) was added. Then plates were 
incubated at 37。C, 5% CO2 for 2 hours. Then 150|al DMSO (dimethyl sulfoxide) was 
added to allow it to stand for 30 minutes at room temperature until the crystal dissolved 
completely. Then OD 540 was recorded by ELISA plate reader (BIO-RAD). Blank 
was set by adding 50\il of MTT solution and 150|il DMSO only. 
Experiments were performed in five repeats. The percentage of survival cell was 
calculated by following equation: 
Mean OD of experiments 
X 100 /o 
Mean OD of controls 
Bars represents the standard error of the data. 
2.4.2 ^H'thymidine incorporation 
5x104 cells were seeded on 24 well plates. After treatments, cells were washed 
twice with PBS. Then Ij iCi ^H-thymidine in 0.5ml RPMI 1640 with 10% serum was 
added to the cells and incubated for 3 hours at 37。C，5% COj. After incubation, cells 
were washed twice with PBS. Volume of 0.5ml of 12% TCA (tetrachoric acid) solution 
was added to precipitate the protein in cells for 1 hour in room temperature and against 
washed twice with PBS. The TCA precipitates were resuspension in 200jLil 1% triton-
X-100 solution with 1% NaOH (IM). Protein concentration was determinated by 
bicinchonic acid assay. Samples at 5[x\ were tested and the assays were done in 
triplicates. 
- 2 3 -
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The ^H-thymidine uptake is calculated by following equation: 
^H-thymidine uptake (counting/jig protein)= 
radioactive counting 
protein concentration of 150/iTriton - X -100respensionsolution 
Bars represents the standard error of the data. 
2.5 RNA extraction 
Cells were grown in monolayer in a 6-well plates or 35mm-dish. Cells were lysed 
directly in culture dish by adding 1ml ofTRIzol Reagent (GIBCO BRL), and passing the 
cell lysate several times through a pipette. Chloroform at volume of 0.2ml was added 
per 1ml of TRIzol Reagent. The eppendroff tubes were shaken vigorously for 15s. 
Then samples were centrifuged at 12，000g for 15 minutes at 4。C. 
Following centrifligation, the upper aqueous phase was collected and transferred to a 
fresh eppendroff tube. Isopropanol at volume of 0.5ml was added and incubated at -
2(rC for 20 minutes, then centrifuge at 12,000g for 10 minutes. The supernatant was 
removed and the RNA pellet was washed once with 1ml of 75% ethanol. RNA pellet 
was dried by air-dry. The sample were dissolved in DEPC-treated water (40-50}il) and 
incubated for 10 minutes at 50-60。C. RNA concentration was measured at OD 260 and 
samples were stored at -70°C. 
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2.6 Competitive Reverse-transcription polymerase chain 
reaction (RT-PCR) of glucose transporters 
First-stand cDNA was reverse-transcribed from 8-10|ig of total RNA results in a 
reaction mixture according to Manufacturer's instruction. (SuperScript™ 
Preamplification system for first strand cDNA Synthesis, GIBCO-BRL). RNA at 
volume of l l f i l (8-10|Lig) in DEPC water was mixed with oligo dT (0.5|Lig) and incubated 
at 70。C for 10 minutes. Then 2^1 lOxPCR buffer, 2^1 O.IM DTT，2)^1 25mM MgCl:， 
and Ijal lOmM dNTP first-strand mixture was added and incubated at 42。C for 5 minutes. 
After addition of 1200U of reverse transcriptase (SupterScriptll RNase H' Reverse 
Transcriptase, GIBCO-BRL), it was then incubated at 42。C 50 minutes, then heated to 
70OC for 15 minutes. Finally, 2U ofRnaseH was added and the mixture was incubated 
at 37。C for 15 minutes. The first-strand cDNA sample was used for PGR reaction 
immediately or stored at -20。C until use. For negative control, reverse transcription 
reaction without reverse transcriptase was performed, as incubated above, to find 
whether DNA contamination. 
PCR reaction was performed from 0.5-2jLtl first strand cDNA as template using 
specific Glutl-5 and GADPH primers as described in the following Table. — 
- 2 5 -
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Gene Annealing Oligonucletoide primers Nucleotide No. Product size 
temperature 
Glut 1F 60。C 5 '-cgtgtccgccgtgctcatggg-3 ‘ 491-511 670 
R 5 '-ccacaaacagcgacacgacag-3 ‘ 1141-1161 
Glut 2 F 62。C 5 '-catgaccgaaaagctatcaac-3 ‘ 189-209 900 
R 5 ’-ccatgtttacagcgccaactc-3 ’ 1069-1089 
Glut 3 F 52。C 5'-ccgtcggactcttcgtcaacc-3 ‘ 481-501 479 
R 5 '-ggatgtcttgggatacatcct-3， 960-940 
Glut 4 F 62°C 5'-caacagataggctccgaagat-3 ‘ 161-181 1320 
R 5 '-ccatagcctccgcaacatact-3 1461-1481 
Glut 5 F 52。C 5'-cgtgcctgcgatcttaatggg-3 ‘ 405-425 581 
R 5 '-tagatctggtccgcgtagtag-3， 966-986 
GADPH F 52。C 5'-accacagtccatgccatcac-3‘ 586-605 451 
R 5，-tccaccaccctgttgctgta-3 ‘ 1018-1037 
PCR was carried out in a total volume of 25uL The reaction tubes contained 
template (0.5-2ul 1st strand cDNA), dNTP (0.2mM), sense and antisense primers (O.l^iM 
each) and 0.5U Taq DNA polymerase (Amersham) in PCR buffer. The reaction tubes 
were incubated in PTC-100™ programmable thermal controller (MJ Research Inc，USA) 
as follows: initial denaturation at 94。C for 5 minutes^ 25-42 cycles of denaturation at 94 
for 1 minute, annealing at 52。C，60。C or 62。C for 1 minute, esxtension at 72。C for 1 
minute and 30 seconds, and enhancement at 72 °C for 5 minutes. The PCR products 
(6iil) were separated by 1% agarose gel electrophoresis. After ethidum bromide 
staining, DNA fragments were visualized by an ultraviolet transilluminatior. The 
intensities of the bands of Glut isoforms were normalized to the GADPH band which 
was amplified simultaneously. 
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2.7 Measurement of 2-deoxy-D-glucose and Fructose transport 
5X104 cells were seeded on 24 well plates. After treatment, cells were wash twice 
with PBS. Then 0.5ml of tritium-labeled reaction mixture containing 2jiCi/ml ^H-2-
deoxy-D-glucose and lOOjaM 2-deoxy-D-glucose in PBS were added to the cells and 
incubated for 5-30 minutes. The reaction was terminated by removing the reaction 
mixture and washing the cells twice with lOmM 2-deoxy-D-glucose. Finally, cells 
were lysed with 200|il 0.1% Triton-X-100. Lysate at volumes of I50[xl were transffered 
to scintillation vials containing 1.5ml scintillant. Radioactivity was recorded in a 
Beckman LS7000 liquid scintillation counter. The remaining 50)^ 1 lysate was used to 
determine protein concentration by bicinchonic acid assay. Samples in I0\i\ were used 
and the each test was performed in triplicates. 
For fructose uptake assay, the same procedures as 2-deoxy-D-glucose uptake assay 
was performed. Instead, the reaction mixture containing O.S^iCi/ml '"^C-fructose and 
ImM fructose and the reaction was terminated by the addition of lOOmM fructose in the 
reaction mixture. 
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2.8 Western blotting 
Cells grown on 6-well plates were trypsinized and washed twice with PBS. Then 
cell pellet was lysed in lysis buffer (80-100^1) containing ImM 
phenylmethylsulfonylfluoride, 1% Triton-X-100，21^ig/ml aprotinin, 0.5)ig/ml leupeptin, 
4.9mM MgCl2, and ImM vanvdate by incubating at room temperature for 30 minutes. 
Then samples were boiled for 10 minutes and stored at -70°C. Protein concentration 
determination was peformed with bicinchonic acid assay (Sigma). 
The protein minigel appartus (Hoefer) vertical electrophoresis system with 8 or 12% 
separation gel and 3% stacking gel was used. The separation gel solution (8%), gel 
solution [1.5 ml 4x running gel solution (0.4% SDS，L5mM Tris-Cl, pH二8.8)]，1.6ml 
polyacrylamide (w/v, 37.5:1 aciylamide:bisacrylamide) and 2.86ml diluted water was 
prepared. Then 30|al 10%(w/v) ammonium persulfate, and l \ i \ N,N,N',N'-
tetramethylethylenediamine (TEMED) per gel solution was added, and the gel was 
casted. The gel solution was immediately overlaied with 70% ethanol and the gel was 
allowed to polymerize for about 30 minutes. The tertiary ethanol should be added 
carefully so as to cause minimum disturbance to the gel surface. The tertiary ethanol 
was discarded and removed excess with a filter. Then 4.5% stacking gel solution 
[1ml 4x stacking gel solution (0.4% SDS, 0.5M Tris-Cl, pH二6.8)，1.2ml polyacrylamide 
(w/v, 37.5:1 acrylamide:bisacrylamide) and 600^1 diluted water] was prepared, then 30)il 
10%(w/v) ammonium persulfate, and 5.3 jal TEMED per gel solution was added. A 
comb was introduced and the gel was allowed to polymerize for 15 minutes. Then, 
comb was removed and washed the wells were with running buffer. The gel 
electrophoresis apparatus were constructed and the reservoir was filled with electrode 
buffer ( 0.025M Tris base, 0.192M glycine, 1% SDS(w/v)). 
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Equal amount of cell protein (25|ig) was loaded onto each lane. The gel was run 
with constant current 20mA/gel for about an hours until the bromophenol blue dye band 
moved near the lower end of the gel. 
The fractionated proteins were electroblotted onto nitrocellulose membrane in 
transfer buffer [50mM tris, 192mM glycine, 20% (v/v) methanol] at 75mA, using a 
minigel Trans-Blot apparatus (Bio-Rad). After blocking with TBS-T (Tris-buffer 
(50mM Tris, 200mM NaCl, pH.7.4) saline with 0.1% Tween-20) containing 5% non-fat 
milk for overnight at 4°C, the membrane was then washed three times with 5ml of TBS-
T for 15 min each and incubated with appropiate primary antibody in 2ml 10% non-fat 
milk at room temperature with constant shaking for 1 hour. The polyclonal anti-rabbit 
antibodies against Glut5 (Research Diagnostic Inc.) was diluted at 1:200 or mdr (Ab-1) 
polyclonal (CalBiochem.) was also diluted at 1:200. The membrane was then washed 
three times with 5ml of TBS-T for 15 minutes each after 1 hour incubation of primary 
antibodies. Finally, membrane was incubated with horsedish peroxidase (HRP)-labeled 
anti-rabbit (Santa Cruz USA) which were diluted 1:1000 in 2ml 10% non-fat milk at 
room temperature with constant shaking for 1 hour. Before developing the membrane 
by chemiluminescent detection system, the membrane was washed three times with 5ml 
of TBS-T for 15 minutes each to wash the excessive secondary antibody. Visualization 
by enzyme chemiluminescence, using the horeseradish peroxidase enzyme, was 
performed according to the manufacturer protocol (ECL Western detection kit; 
Amersham Life Science). 
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2.9 Flow cytometry 
2.9.1 Measurement of cellular accumulation of fluorophore-labeled 
oligonucleotide 
After exposure of cells to fluorescein isothiocyanate (FITC, green fluorescence)-
labeled phosphorothioate oligonucleotide for different hours (0-24 hours), cells were 
trypsinized and washed twice with PBS. Then signals emitted from the samples were 
analyzed using a flow cytometry (Becton-Dickinson FACSort ). Green fluorescence 
was monitored with 530/30nm bandpass filter, and photomultiplier tube pulses were 
amplified logarithmically. Ten thousand cells were counted. Live cells were gated 
using their morphological properties (forward scatter [FSC] and side scatter [SSC], set 
on logarithmic mode), and signal from dead cells were rejected. The mean fluorescence 
intensity of the population of oligonucleotide treated cells was calculated using 
histograms and was expressed in arbitrary units using a LYSIS I I software program 
(Becton-Dickinson). 
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2.10 Design of antisense oligonucleotide 
The mRNA sequence of the Glut5 were searched in http://www.ncbi.nlm.nih.gov, 
from GenBank. 
The length of 15 to 30 mer is sufficient to guarantee sequences specificity. 
BLAST search was performed to confirm the antisense oligonucleotides designed 
specifically for the Glut5 gene. No appreciable overlapping with other human mRNAs 
was found. Figure 2.10 have illustrated the general principles in the design of antisense 
oligonucleotide using 7015 as example. 
70 75 80 85 90 
cDNA sequence (Sense OND) 5'-AGAGCAAGCATGGAGCAACAGGAT-3' 
Reverse sequence 3'-CGTTCGTACCTCGTT-5' 
: X ： 
Antisense Oligonnculeotide 3'-TTGCTCCATGCTTGC-5' 
Figure 2.10 Antisense oligonucleotide is complementary to the mRNA sequence and 
displayed 5'->3'. The 15 mer antisense shown here is targeted to the Glut5 gene, 
flanking the AUG start codon. 
The phosphorothioate oligonucleotides and FITC-labeled phosphorothioate 
oligonucleotides were purchased from GIBCO-BRL or Gold Pactific Enterprises. 
Oligonucleotides were dissolved in PBS and stored at -20。C 
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Sequences of the sense and random oligonucleotides of Glut5 have been listed in 
the following table: 
Name Region Sequence Length Nucleotide 
No. 
5, • 3' 
S-7015 Start codon GCAAGCATGGAGCAA 15 70-84 
S-40415 Coding region TCGTGCCTGCGATCT 15 404-418 
S-96615 Coding region CTACTACGCGGACCA 15 966-980 
S-157115 Stop codon CGGAACAGTGACTCT 15 1571-1585 
S-4615 5'-non-coding TGAGCGGCACTCTGC 15 46-60 
S-7021 Start codon G CAAGCATGGA GCAACAGGAT 21 70-90 
R-7015 Random CTCTTGTCGGTCCAT 15 70-84 
Table 2.10.1 Sequence of sense oligonucleotide 
Sequences of the antisense oligonucleotides of Glut5 have been listed in the 
following table: 
Name Region Sequence Length Nucleotide 
No. 
5' • 3’ 
AS-7015 Start codon TTGCTCCATGCTTGC 15 70-84 
AS-40415 Coding region AGATCGCAGGCACGA 15 404-418 
AS-96615 Coding region TGGTCCGCGTAGTAG 15 966-980 
AS-157115 Stop codon AGAGTCACTGTTCCG 15 1571-1585 
AS-4615 5'-non-coding GCAGAGTGCCGCTGA 15 46-60 
AS-7021 Start codon ATCCTGTTGCTCCATGCTTGC 21 70-90 
Table 2.10.2 Sequence of antisense oligonucleotide 
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Sequences of the FITC-labeled oligonucleotides of GlutS targeting start codon have 
been listed in the following table: 
Name Sequence Length Nucleotide 
No. 
5丨 • 3丨 
AS-7015 TTGCTCCATGCTTGC 15 70-84 
AS-7021 ATCCTGTTGCTCCATGCTTGC 21 70-90 
AS-7030 CATGCTCTG ATCCTGTTGCTCCATGCTTGC 30 70-89 
Table 2.10.3 Sequence of FITC-labeled oligonucleotide 
Sequence of Glutl and GlutS antisense and sense have been listed in the following table: 
Name Sequence Length Nucleotide 
No. 
5’ > y 
AS-Gl 16915 CCATGGCAGCGCTGC 15 169-183 
S-Gl 16915 GCAGCGCTGCCATGG 15 169-183 
AS-G3 7015 CTCGCTGGGATCATG 15 70-84 
S-G3 7015 CATGATCCCAGCGAG 15 70-84 
Table 2.10.3 Sequence of Glut l and Glut3 antisense and sense 
oligonucleotides 
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2.11 ATP assay 
Cells were seeded on 6-well plates and washed twice with PBS. Cells were 
trypsinzed and cell pellets were lyzed by adding 55|ul 6% trichloroacetic acid solution. 
The mixture was mixed well and allowed to stand for 10 minutes at 4。C. The protein-
free supernatant was obtained by centrifligated at 5000g for 10 minutes at 4。C. ATP 
content was assessed using a Sigma kit. Briefly, 1ml buffer solution (18mM 3-
phosphoglyceric acid, Mg2+ and EDTA) and 1.7ml of deionized water were mixed well 
with 0.3mg NADH. Then 450}il of above solution was mixed with 50|il supernatant 
sample. The initial absorbance was read and recorded versus water as reference at 
340nm using a spectrophotometer . The reaction was initiated by addition of 
enzyme mixture (phosphoglycerate kinase (PGK) and glyceraldehyde phosphate 
dehydrogenase (GAPD)). The decreased absorbance of NADH was recorded at 340mn. 
The following were the enzyme reactions: 
ATP + 3-Phosphoglycerate PGK ADP + 1,3-Diphosphoglycerate 
• 
1,3-Diphosphoglycerate + NADH GAPD Glyceraldehyde-3-P + NAD + P 
• 
The TCA pellets were resuspension in 200^1 1% triton-X-100 solution with 1% NaOH 
(IM). Protein concentration was determinated by bicinchonic acid assay (5jil for each 
test and repeated 3 times). ATP concentration in cells was calculated from the ATP 
standard curve using linear regression statistics. 
ATP concentration (uM/mg protein) = AA x slope of standard curve 
protein concentration of TCA pellet (mg) 
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2,12 Animals studies 
Male or Female Balb/c nu:nu nude mice aged 6-8 weeks were fed with autoclaved 
tape water ad libitum with animal diet (PICO LAB® Rodent Diet). The animal protocol 
was approved by the Animal Research Ethics Committee, The Chinese University of 
Hong Kong. The mice were housed in filter-top cages and were bred at the Laboratory 
Animal Service Center of The Chinese University of Hong Kong under pathogen-free 
I condition. 
! In experiment designed to compare different oligonucleotide, mice were randomly 
assigned into each of three groups (antisense, sense and control group). 2x10? Caco-2 
cells suspensed in saline were injected subcutaneously (S.C.) into the posterior back of 
the athymic BALB/c nude mice and allowed it to growth for four weeks. Mice (three 
per group) were injected on alternate day for 20 days (ten total doses) with 
phosphorothioate oligonucleotide (sense and antisense group, 4mg/kg/injection), or 
control group (Saline, 0.9% NaCl, pH 7.4). Oligonucleotides were administered 
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CHAPTER 3 
OPTIMIZATION OF PHOSPHOROTHIOATE 
ANTISENSE OLIGONUCLEOTIDE DELIVERY 
BY LIPOFECTIN 
3.1 Introduction 
Antisense oligonucleotide must enter cells and interact with pre-mRNA and mRNA 
in the nucleus and cytoplasm in order to exert their pharmacological and biological 
effects. In most cell culture studies, free antisense oligonucleotides are initially 
ineffective and only become active in the presence of appropriate facilitator or delivering 
carrier. Cationic liposome is one of the most widely used delivery carriers for in vitro 
assay. A variety of commercially available cationic lipids which can be used for this 
purpose are listed in following table: 
Cationic lipid Commercial source 
LipofectACE Life Technologies 
Lipofectin Life Technologies 
LipofectAMINE Life Technologies 
CellFECTIN Life Technologies 
DDAB Sigma 
DC-Chol Sigma 
DOTAP Boehringer Manneheim 
Transfectam Promega 
TransFast Promega 
Tfx-10, Tfx-20, and Tfx-50 Promega — 
ProFection-CaPO, - Promega 
Profection-DEAE-Dextran Promega 
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Lipofectin is selected in this study. Lipofectin reagent is a 1:1 (w/w) liposome 
formulation of cationic lipid N-[l-(2,3-dioleyloxy)propyl]-n,n,n,-trimethylammonium 
chloride (DOTMA) and dioleyl phosphotidylenthanolamine (DOPE). The cationic 
lipid，DOTMA binds the negatively charaged oligonucleotide. In addition to cationic 
lipid, a second helper lipid, DOPE is added to the formulation to assist in the release of 
oligonucleotides from the endosome compartment of the cell. 
The optimized condition for using Lipofectin in various cell systems must be 
obtained through trial and error. Cell type has a dramatic effect on total uptake, kinetics 
of uptake, and pattern of subcellular distribution. Tissue culture conditions, such as the 
type of medium, degree of confluence and the presence of serum, can exhibit enormous 
effects on uptake. Each cell line can demonstrate individual response in terms of both 
effectiveness and toxicity for the Lipofectin reagent. Thus, in this chapter, studies had 
been concentrated in optimizing the conditions of using Lipofectin in Caco-2 cells in the 
presence of FITC-phosphothioated antinsense oligonucleotide. 
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3.2 Measurement of oligonucleotide uptake 
The internalization of phosphorothioate FITC-labelled oligonucleotide was 
measured by flow cytometry. Cells were seeded on 24-well plates and 
phosphorothioate FITC-labelled oligonucleotide was added to the cells and allow to 
incubate at 37。C for 0-24 hours in serum free and antibiotic free medium. Cells were 
trypsinized by trypsin-EDTA and washed twice with PBS. Then cells were 
resuspended in 500)il PBS. 
The relative mean fluorescence intensity was determined for a population of 10,000 
cells for each experiment using a log channel amplifier. The mean fluorescence 
intensity of the populations of oligonucleotide treated cell was calculated using 
histograms and was expressed in arbitrary units. In the histograms, "FLl-Height" was 
plotted against "Events" using the program WINMDI 2.6. "FLl-Height" indicated the 
green fluorescent intensities in cells while "Events" reflected the mean log-FITC value. 
However the Mean log-FITC value was dependent on the setting ofPMT amplifications. 
Thus, the value must compare with the control. 
Sequences of the FITC-labeled oligonucleotides of GlutS targeting start codon are 
designed and listed in the following table: 
- Name Sequence No. of Nucleotide 
, nucleotide numbering 
5' ^ 3, on Gluts 
AS-7015 TTGCTCCATGCTTGC 15 70_84 
AS-7021 ATCCTGTTGCTCCATGCTTGC 21 70-90 
AS-7030 CATGCTCTG ATCCTGTTGCTCCATGCTTGC 30 70-89 
Table 3.2 Sequence of FITC-labeled oligonucleotide 
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3.2.1 Lipofectin as a delivery system for the oligonucleotide uptake 
In order to follow the internalization of FITC labeled oligonucleoitdes, flow 
cytometry was used. 1x10^ Caco-2 cells were seeded on 24-well plates. For 
negative control, only serum and antibiotic free medium was added. 2j iM FITC-labeled 
phosphorothioate oligonucleotide was incubated with Caco-2 cells for 5 hours in serum 
and antibiotic free medium. When same amount of Lipofectin (w/w) was added, the 
intracellular FITC-labelled oligonucleotide increased 3 folds compared with that when 
FITC-labeled phosphorothioate oligonucleotide alone was added (Figure/Table 3.2.1.1). 
Another commercially available transfection reagent Fugene6 was used to compare with 
the effect of Lipofectin. lO^iM FITC-labeled phosphorothioate oligonucleotide was 
incubated with Caco-2 cells for 5 hours in serum and antibiotic free medium with 
Fugene6 or FITC-labelled oligonucleotide only. It is found that Fugene6 (177units) 
was not as effective as Lipofectin (270units) i f the same amount of transfection reagent 
and oligonucleotide were added (Table 3.2.1.2). The FITC-labelled oligonucleotide 
only increased 1.5 fold in this way. 
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Mean Log FITC 
Negative control 3 33 
FITC-labelled oligonucleotide 25.13 
FITC-labelled oligonucleotide with Lipofectin (w/w, 1:1) 75.78 
Table 3.2.1.1 The value of Mean Log FITC for various conditions as 
described in Figure 3.2.1.1 
Mean Log FITC 
Negative control 5 
FITC-labelled oligonucleotide with Lipofectin (w/w, 1:1) 269.99 
FITC-labelled oligonucleotide with Fugene6 (w/w, 1:1) I77.3 
Table 3.2.1.2 The effect of another commercially available transfection 
reagent Fugene6 (non-liposome type) on FITC-ODN uptake 
was compared with that of Lipofectin. 
. . / \ A 
” vA\ 
10。 10^  102 ~ 1 0 ^ 
— FL1-Height 
Figure 3.2.1.1 Effect of Lipofectin on FITC-ODN uptake. 
1x105 Caco-2 cells were seeded on 24 well plates. For negative control, only serum-
free medium was added and incubated at 37。C for 5 hours (Left curve). The data on 
_ uptake when 2 _ FITC conjugated 15mer FITC-phoshporothioate oligonucleotide 
incubated with Lipofectin (w/w) in serum-free medi腿（Right curve) or FITC-labeled 
oligonucleotide only (Middle Curve) were recorded. 
- 4 0 -
i 
Chapter 3 O p t i m i z a t i o n o f P h o s p h o r o t h i o a t e A n t i s e n s e O l i g o n u c l e o t i d e D e l i v e r y by [ . ipofcc t in 
3.2.2 Effect of Lipofectin ratio on the oligonucleotide uptake 
The effect of Lipofectin concentration on the cellular uptake of oligonucleotide was 
studied by addition of 4jaM (i.e. 3.84|ig in 200^1 serum free and antibiotic free medium) 
phosphorothioate FITC-conjugated 15 mer antisense oligonucleotide and different 
concentrations (w/w) of Lipofectin for 5 hours. Figure 3.2.2 shows the relationship 
between the uptake and the oligonucleotide and Lipofectin ratio namely 1:1 (3.84}ig : 
3.84昭)，1:2 (3.84|ag : 7.68|ig) and 1:4 (3.84|ig :15.36|ig). It is found that about 2 
fold and 4 fold increases in oligonucleotide uptake could be observed when the 
Lipofectin ratio increased to 1:2 and 1:4 respectively (Figure 3.2.2. A/Table 3.2.2). The 
increase of oligonucleotide uptake was proportional to the increase in the Lipofectin 
concentration (Figure 3.2.2 B). 
3.2.3 Effect of oligonucleotide concentration on the oligonucleotide 
uptake 
The effect of Lipofectin complexed with a range of oligonucleotide concentration 
on the cellular uptake of oligonucleotide was determined in Figure/Table 3.2.3. 
Lipofectin was added to aid the transfection of oligonucleotde and oligonucleotide to 
Lipofecin ratio was 1:1 (w/w) for 5 hours in 37。C. It is observed that increasing 
oligonucleotide concentrations resulted in proportionally increased cellular uptake when 
the concentration of oligonucleotide increased from 2\^M to lOjuM. The 
oligonucleotide uptake is concentration dependent, as the concentration of 
oligonucleotide increased, the uptake proportionally increased. -
- 4 1 -
i 
Chapter 3 Optimization of Phosphorothioate Antisense Oligonucleotide Delivery by Lipofectin 
Lipofectin ratio Mean Log FITC 
Negative control 5.19 
Lipofectin ratio 1:1 269.66 
Lipofectin ratio 1:2 621.55 
Lipofectin ratio 1:4 1258.21 
Table 3.2.2 The value of Mean Log FITC for various conditions as 
described in Figure 3.2.2 
^ A 
I K 
7 b； 1 
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• • 
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Z 
oligonucleotide to Lipofectin ratio 
Figure 3.2.2 Effect of Lipofectin ratio on FTTC-ODN uptake was 
compared. 
1x10^ Caco-2 cells were seeded on 24 well plates. (A) For negative control, only 
serum-free medium was added and incubated at 37。C for 5 hours (Red curve). Aliquots 
of 4|xM FITC conjugated 15-mer phoshporothioate oligonucleotide incubated with 
different concentrations of Lipofectin in serum-free medium. The oligonucleotide and 
Lipofectin was 1:1 (Black curve) (w/w)，1:2 (Green curve) and 1:4 (Blue curve) 
resprectively. (B) The mean log FITC was recorded for each incubation condition. 
- 6 2 -
Chapter 3 Optimization of Phosphorothioate Antisense Oligonucleotide Delivery by Lipofcctin 





Table 3.2.3 The value of Mean Log FITC for various conditions as 
described in Figure 3.2.3 
1 A ‘ 
10° 101 102 103 104 g)150 • 
. 5 。 • • • 
0 L _ _ I _ _ H i _ _ I _ _ I H _ 1 _ _ H _ _ I 
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concentration of 
oligonucleotide (uM) 
Figure 3.2.3 Effect of oligonucleotide concentration on FITC-ODN uptake. 
1x105 Caco-2 cells were seeded on 24 well plates. For negative control, only serum-
free medium was added and incubated at 37。C for 5 hours (Red Curve). The data a 
uptake when 2|iM (Blue curve), 5[iM (Green curve) and 1 0 _ (Black curve) FITC 
conjugated 15mer phoshporothioated oligonucleotide incubated with Lipofectin (1:1, 
w/w) were recorded. (B) The mean log FITC was recorded for each incubation 
condition. 
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3.2.4 Effect of incubation time on the oligonucleotide uptake 
Incubation time is also a critical criterion to affect the cellular uptake of 
oligonucleotide. Figure/Table 3.2.4 shows results of experiment performed to 
determine the time course of oligonucleotide uptake in Caco-2 cells with or without 
addition of Lipofectin. The uptake reached to maximum at 24 hours incubation in both 
cases. The amount of oligonucleotide clearly increased visibly over 0-24 hours 
incubation with Lipofectin. However, without Lipofectin, the oligonucleotide uptake 
increased rapidly at 0-15 hours incubation and level led off at 15-24 hours. 
3.2.5 Effect of oligonucleotide length on cellular uptake 
Theoretically, oligonucleotide with 15-30-mer could bind to the target mRNA 
specifically. The longer the oligonucleotide, the cellular uptake is lower. lOjaM of 15-
mer (9.6|ig), 21-mer (13.44|^g) and 30-mer (19.2^g) were incubated with 200|il serum 
free and antibiotic free medium. Lipofectin were added to aid the uptake of 
oligonucleotide and their concentration ratio is 1:1 (w/w). As shown in Figure/Table 
3.2.5，comparing the 15-mer and 21-mer, or 30-mer, it is found that 15-mer was more 
effective in cellular uptake than the other two oligonucleotide with longer length. The 
mean log uptake of fluorescence of 15-mer oligonucleotide was 312.9. However, i f the 
uptake results of 21 mer (213.68) and 30mer (229.05) were compared with that of 15-mer, 
the uptake data of 21-mer and 30-mer were lower than that of 15-mer. 
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Time With Lipofectin Without Lipofectin 
control 3.38 3.38 
2 75.78 25.13 
7 96.3 47.3 
15 106.6 65.31 
24 140.62 71.58 
Table 3.2.4 The values of Mean Log FITC for various conditions as 
described in Figure 3.2.4 
160 [El with 
140 r r ^ r — lipofectin 
。120 _ — • without 
t 100 - Rv| Is： l ipofectin 
D) - - ：：：  ：：： >：•：： 
•2 80 ———：:•:：：——：：:：:：——：：:：:：—— 
i 60 —_一 _一 
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incubation time (hours) 
Figure 3.2.4 Time course for FITC-ODN cellular uptake with or without 
Lipofectin. 
1x105 Caco-2 cells were seeded on 24 well plates. For negative control, only serum-
free medium was added and incubated at 37。C. FITC conjugated 15-mer 
phoshporothioate oligonucleotide were added and incubated for 1,1, 15 and 24 hours. 
Lipofectin (1:1, w/w) was added in dotted line bars while Lipofectin was not added in 
solid bars. The data were recorded in various conditions. 
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length of oligonucleotide mean of uptake 
15mer 312.9 
21 mer 213.68 
30 mer 229.05 
Table 3.2.5 The value of Mean Log FITC for various conditions as 
described in Figure 3.2.5 
350 r -
I 250 — H 
15 mer 21 mer 30 mer 
Length of oligo 
Figure 3.2.5 The effect of oligonucleotide length on the FITC-ODN cellular 
uptake. 
1x105 Caco-2 cells were seeded en 24 well plates. 10|uM FITC conjugated 15mer 
phoshporothioate oligonucleotides with the length of 15-mer, 21-mer and 30-mer were 
added with Lipofectin (1:1, w/w) and were incubated for 24 hours in serum-free medium. 
The data were recorded in various conditions. 
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3.3 Effect of Lipofectin on cell viability 
The toxicity of Lipofectin was tested on Caco-2 cell for a range of concentrations. 
0 to 15|ug (corresponding to final concentration of 0 - 3 1 _ of Lipofectin were diluted 
into 100|il of serum, antibiotic free RPMI 1640 medium. Cells were mixed with the 
cationic lipid solution, Lipofectin, and incubated for 24 hours. Figure 3.3 shows that 
the maximum tolerable of net Lipofectin levels, defined as > 80% of untreated cell 
survival for Caco-2 cells, was about I f the concentration of Lipofectin increased 
to 31 jaM, the net toxicity increased to about 40%. 
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Figure 3.3 The effect of Lipofectin on Caco-2 cell viability. 
The net toxicity of Lipofectin was measured by MTT assay. IxlO'^ Caco-2 cells were 
seeded on 96 well plate. 0-15|ig of Lipofectin in serum-free medium were incubated 
for 24 hours with the cells. The cell viability was measured by MTT assay. Each 
point represents the mean of five repeats and the bar represents 土SD. The cell viability 
was compared with the negative control in which only serum free medium was used. 
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CHAPTER 4 
IN VITRO EFFECT OF ANTISENSE 
OLIGONUCLEOTIDES AGAINST GLUCOSE 
TRANSPORTERS ON CACO-2 CELL 
4.1 Introduction 
Glycolysis is known to be the primary energy source in cancer cells. Glucose 
transporters are membrane proteins that transport sugars such as glucose, galactose and 
fructose. Facilitated-difflision glucose transporter (Glut family, Glutl, 2, 3，4, 5 and 7) 
are known to exist in mammalian cells. Among them, Glut5 is an isoform in the 
facilitated-difflision glucose transporter family, which transports fructose and is 
expressed in the small intestine, kidney and testis in the human. In the small intestine, 
Glut5 is present in the absorptive epithelial cells, which are localized along the apical 
brush borders. It is proposed that Glut5 plays an important role in the uptake of 
fructose from the intestinal lumen. Transepithelial transfer of dietary fructose seems to 
be carried out by the combined action of apical entry of fructose through Glut5 and 
subsequent basolateral exit via Glut2. 
Caco-2 is the human colon adenocarcinoma cell line. It has been reported that 
Caco-2 cells express facilitated transport system at the apical and basolateral surfaces. 
Caco-2 cells express high levels of Glutl, Glut3 and GlutS (Mahraoui et al., 1994). 
Glutl isoform localizes to the basolateral membrane, Glut3 to the apical membrane. 
- G l u t s , on the other hand, has a pattern of distribution that is intermediated between that 
of Glutl and that of Glut3, being found at both the apical and basolateral membrane. 
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4.2 Design of Antisense Oligonucleotides against Glucose 
Transporters gene 
Usually the length of 15 to 30-mer is sufficient to guarantee sequences specificity. 
Then BLAST search was performed to confirm the antisense oligonucleotides designed 
are specific for the Glut5 gene. No appreciable overlapping with other human mRNA 
was found. Phosphorothioate modified backbone was selected for antisense studies to 
improve oligonucleotide stability. 
Sequences of the sense and random oligonucleotides of GlutS are designed and 
listed in the following table: 
Name Region Sequence No. of Nucleotide 
5 丨 • 3’ nucleotide numbering 
of Gluts 
S-7015 Start codon GCAAGCATGGAGCAA 15 
S-40415 Coding region TCGTGCCTGCGATCT 15 404-418 
S-96615 Coding region CTACTACGCGGACCA 15 966-980 
S-157115 Stop codon CGGAACAGTGACTCT 15 1571-1585 
S-4615 5'-non-coding TGAGCGGCACTCTGC 15 46-60 
S-7021 Start codon GCAAGCATGGAGCAACAGGAT 21 70-90 
R-7015 Start codon CTCTTGTCGGTCCAT 15 
Table 4.2.1 Sequences of sense and random control oligonucleotides of 
Glut 5 
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Sequences of the antisense oligonucleotides of GlutS are designed and listed in the 
following table: 
Name Region Sequence No. of Nucleotide 
5 丨 • 3’ nucleotide numbering on GlutS. 
A S - 7 0 1 5 S t a r t codon TTGCTCCATGCTTGC 15 
AS-40415 Coding region AGATCGCAGGCACGA 15 404-418 
AS-96615 Coding region TGGTCCGCGTAGTAG 15 966-980 
AS-157115 Stop codon AGAGTCACTGTTCCG 15 1571-1585 
AS-4615 5'-non-coding GCAGAGTGCCGCTGA 15 46-60 
AS-7021 Start codon ATCCTGTTGCTCCATGCTTGC 21 70-90 
Table 4.2.2 Sequences of antisense oligonucleotides of Gluts 
Sequence of Glutl and Glut3 antisense and sense oligonucleotide have been listed in the 
following table: 
Name Sequence No. of Nucleotide 
, nucleotide numbering on 
5' • 3' Glut5 
AS-Gl 16915 CCATGGCAGCGCTGC 15 169-183 
S-Gl 16915 GCAGCGCTGCCATGG 15 169-183 
AS-G3 7015 CTCGCTGGGATCATG 15 70-84 
S-G3 7015 CATGATCCCAGCGAG 15 70-84 
Table 4.2.3 Sequence of Glutl and Glut3 antisense and sense 
oligonucleotides 
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4.3. Antisense effect of different regions of antisense 
oligonucleotide 
The cytotoxic effects of five antisense oligonucleotides flanking different regions of 
the Glut5 gene on Caco-2 cells were studied. The cells viability were measured by 
MTT assay. As mentioned before, G54615 is the 5' cap region, G57015 is the flanking 
start codon, G540415 and G596615 falls in the coding region and G5157115 is the 
antisense oligonucleotide targeting the stop codon. Comparing the effect of five 
antisense oligonucleotides flanking different regions (Figure 4.3, A) at 8|iM, the survival 
rates in descending order are 94% in G54615, 58% in G596615, 47% in G5157115, 38% 
in G540415 and 38% in G57015 treatment. However, Figure 4.3 (B) shows that there is 
no different in cell viability between the sense oligonucleotide and antisense 
oligonucleotide in G54615 (II)，and G596615 (III) treatment. For G5157115 (I), and 
G596615 (IV) and G540415 (IV), the survival rate was about 60% when S^iM of sense 
control added. The sense effect of G57015 (V) which flanks the start codon was less 
significant, the survival rate was higher than 80% when O-S^iM sense control added. 
The cell viability is measured by MTT assay. 
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Figure 4.3 (A) Comparison of cytotoxic effects of antisense oligonucleotide 
flanking different regions on Caco-2 cells. 
Ix lO' cells were seeded on 96 well plates. 0-8|LIM of antisense oligonucleotides (G54615 
is the 5' cap region, G57015 is the flanking start codon, G540415 and G596615 falls in 
the coding region and G5157115 is the antisense oligonucleotide flanking the stop codon) 
with Lipofectin (1:1，w/w) were added to cells and allowed for 24 hours transfection in 
serum, antibiotics-free medium. Then cells were further incubated for 48 hours in 
complete medium (10% RPMI and 5% penicillin-streptomycin). The cell viability was 
measured by MTT assay. The value for untreated control cells was set at 100%. Data 
shown are representative of five duplicates means and 士SD. 
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Figure 4.3 (B, I) The cytotoxic effects of sense and antisense effect of G5 157115， 
flanking stop codon on Caco-2 cells. 
1x104 cells were seeded on 96 well plates. 0-8jaM G5157115 flanking stop codon (15-
mer oligonucleotide) of antisense and sense oligonucleotides with Lipofectin (1:1，w/w) 
were added to cells and allowed for 24 hours transfection in serum, antibiotics-free 
medium. Then cells were further incubated for 48 hours in complete medium. The 
cell viability was measured by MTT assay. The value for untreated control cells were 
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Figure 4.3 (B, II) The cytotoxic effects of sense and antisense effect of G5 4615, 
5，non-coding region on Caco-2 cells. 
IxlO' cells were seeded on 96 well plates. O-S i^M G5 4615 5，non-coding region (15-
mer oligonucleotide) of antisense and sense oligonucleotides with Lipofectin (1:1, w/w) 
were added to cells and allowed for 24 hours transfection in serum, antibiotics-free 
medium. Then cells were further incubated for 48 hours in complete medium. The 
cell viability was measured by MTT assay. The value for untreated control cells were 
set at 100%. Data shown are representative of five duplicates means and 土SD. 
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Figure 4.3 (B, III) The cytotoxic effects of sense and antisense effect of G5 96615, 
flanking coding region on Caco-2 cells. 
1x104 cells were seeded on 96 well plates. 0-8|iM G5 96615 flanking coding region (15-
mer oligonucleotide) of antisense and sense oligonucleotides with Lipofectin (1:1, w/w) 
were added to cells and allowed for 24 hours transfection in serum, antibiotics-free 
medium. Then cells were further incubated for 48 hours in complete medium. The 
cell viability was measured by MTT assay. The value for untreated control cells were 
set at 100%. Data shown are representative of five duplicates means and 士SD. 
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Figure 4.3 (B, IV) The cytotoxic effects of sense and antisense effect of G5 40415， 
flanking coding region on Caco-2 cells. 
1x10' cells were seeded on 96 well plates. O-S^iM G5 40415 flanking coding region (15-
mer oligonucleotide) of antisense and sense oligonucleotides with Lipofectin (1:1，w/w) 
were added to cells and allowed for 24 hours transfection in serum, antibiotics-free 
medium. Then cells were further incubated for 48 hours in complete medium. The 
cell viability was measured by MTT assay. The value for untreated control cells were 
set at 100%. Data shown are representative of five duplicates means and 土SD. 
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Figure 4.3 (B, V) The cytotoxic effects of sense and antisense effect of G5 7015, 
flanking start codon on Caco-2 cells. 
IxlO" cells were seeded on 96 well plates. 0-8^iM G5 7015 start codon (15-mer 
oligonucleotide) of antisense and sense oligonucleotides with Lipofectin (1:1，w/w) were 
added to cells and allowed for 24 hours transfection in serum, antibiotics-free medium. 
Then cells were further incubated for 48 hours in complete medium. The cell viability 
was measured by MTT assay. The value for untreated control cells were set at 100%. 
Data shown are representative of five duplicates means and 士SD. 
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4.4 Antisense and Sense effect of oligonucleotide against 
start codon (G5 7015) on Caco-2 cells 
4.4.1 Effect of oligonucleotide to Lipofectin ratio on cell viability 
In order to determine the toxicity of Lipofectin/oligonucleotide complex, same 
concentration of oligonucleotide was incubated with different concentrations of 
Lipofectin (w/w). Cells were seeded on 96-well plates, and 100|il of 
oligonucleotde/Lipofectin complex was incubated with cells for 24 hours. 5jiM (i.e. 
2.4|ig) oligonucleotide was incubated with three different concentrations, namely 2A^g 
(1:1), 4.8)ag (1:2) and 7.2}ig (1:3) of Lipofectin. Antisense (G5 7015) and control with 
random sequence (random control) were applied. Then cells were further incubated for 
48 hours. Cells viability were determined by MTT assay. Figure 4.4.1 shows that the 
survival of random control decreased as the oligonucleotide to Lipofectin ratio increased 
from 1:1 to 1:3. Lower amounts of Lipofectin caused less toxicity. I f the 
oligonucleotide to Lipofectin was 1:1，the toxicity of random control was about 0%. 
Nevertheless, i f the Lipofectin ratio increased to 1:2’ then the toxicity of random control 
increased to 56%. I f the ratio further increased to 1:3，the toxicity of random control 
increased to 76%. There is most significant different on cell viability between random 
and antisense oligonucleotide if the ratio is 1:1 compared with oligonucleotide and 
Lipofectin ratio was 1:2 or 1:3. 
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Figure 4.4.1 Effect of oligonucleotide to Lipofectin ratio on cell viability of 
Caco-2 cells. 
1x104 cells were seeded on 96-well plates. Cell viability was measured by MTT assay. 
Survival of Caco-2 cell after 24 hours exposure to antisense oligonucleotide and 
random oligonucleotide in serum free medium. Then cells were further incubation for 
48 hours in complete medium. The oligonucleotide to Lipofectin ratio (w/w) were 1:1， 
1:2 and 1:3. The value for untreated control cells were set at 100%. Data shown are 一 
representative of five duplicates means and 土SD. 
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4.4.2 Dose-Response Study: effect of concentration of antisense 
oligonucleotide on cell viability 
The concentration effect of antisense oligonucleotide (G5 7015) on cell viability 
was studied. Cells viability was tested by MTT assay. The concentration 
dependence of antisense effect was demonstrated by using a range of concentration of 
oligonucleotide and Lipofectin ratio. Figure 4.4.2 (A) shown that O-lO^iM 
oligonucleotide was incubated with same concentration of Lipofectin (w/w). The 
percentage of cell survival of sense controls was higher than 80%. However, the 
percentage of survival decreased as the concentration of antisense oligonucleotide 
increased. When the antisense oligonucleotide concentration was 1.25|iM, 2.5|iM, 
and lO^iM, the survival rate was 84%, 78%, 65% and 47% respectively. 
Comparing results in Figure 4.4.2 (A) with (B), i f antisense oligonucleotide to Lipofectin 
increased from 1:1 to 1:2 the antisense effect increased, but on the same time, the 
percentage of viability decreased to 67%, 71% and 50% when L25|aM, 2.5)iM and 
sense control added. 
4.4.3 Effect of length of oligonucleotide on cell viability 
Oligonucleotides with different lengths, which were 15-mer and 21-mer, were used -
to study the effect of oligonucleotide length on cell viability. Figure 4.4.3 (B) shows 
that the survival rates of antisense oligonucleotide (targeting the start codon) with 15 
nucleotides or 21 nucleotides were about the same at concentration of O-lOjuM. Also, 
the sense control did not give much toxicity in 21-mer oligonucleotide (Figure 4.4.3 (A)) 
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Figure 4.4.2 (A) The effect of concentration of antisense oligonucleotide on cell 
viability (oligonucleotide to Lipofectin ration is 1:1). 
1x104 cells were seeded on 96-well plates. O-lO^iM G5 7015 antisense and sense 
oligonucleotides with Lipofectin (1:1, w/w) were added to cells and allowed for 24 hours 
transfection in serum, antibiotics-free medium. Then cells were further incubated for 
48 hours in complete medium. The cell viability was measured by MTT assay. The 
value for untreated control cells were set at 100%. Data shown are representative of 
five duplicates means and 土SD 
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Figure 4.4.2 (B) The effect of concentration of antisense oligonucleotide on cell 
viability (oligonucleotide to Lipofectin ration is 1:2). 
1x10" cells were seeded on 96 well plates. 0-5|aM G5 7015 antisense and sense _ 
oligonucleotides with Lipofectin (1:2，w/w) were added to cells and allowed for 24 
hours transfection in serum, antibiotics-free medium. Then cells were further incubated 
for 48 hours in complete medium. The cell viability was measured by MTT assay. 
The value for untreated control cells were set at 100%. Data shown are representative 
of five duplicates means and 土SD 一 
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Figure 4.4.3 (A) The effect of 21 mer antisense oligonucleotide (G5 7015) on cell 
viability 
—1x104 cells were seeded on 96-well plates. 0-10|iM G5 7015 (21-mer) antisense and 
sense oligonucleotides with Lipofectin (1:1，w/w) were added to cells and allowed for 24 
hours transfection in serum, antibiotics-free medium. Then cells were further incubated 
for 48 hours in complete medium. The cell viability was measured by MTT assay. 
The value for untreated control cells were set at 100%. Data shown are representative 
of five duplicates means and 土SD 
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Figure 4.4.3 (B) Comparison of the length of antisense oligonucleotides on cell 
viability of Caco-2 cells. 
O-lO^iM antisense oligonucleotide (15-mer and 21-mer) with same amount of Lipofectin 
complex (w/w, 1:1) were exposure to the cells for 24 hours in serum, antibiotics-free 
medium, and then the cells were further exposed for 48 hours in complete medium. 
Cells viability was measured by MTT assay. The value for untreated control cells was 
set at 100%. Data shown are representative of five duplicate means and 土SD. 
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4.4.4 Time-Response Study: effect of antisense oligonucleotide on 
cell viability 
The anti-proliferative effect of antisense oligonucleotide against Glut5 on Caco-2 
cells was assessed by H^-thymidine uptake. After the cells were exposed to or 
antisense and sense (control) oligonucleoitde for 24 hours, tf-thymidine 
incorporation at 24, 48 and 72 hours were then measured. Figure 4.4.4 shows that anti-
proliferative effect of antisense oligonucleotide occurred at 24, 48 hours and 72 hours. 
Figure 4.4.4 (A) shows that anti-proliferative effect of antisense oligonucleotide 
increased from 4% to 29% i f the antisense oligonucleotide concentration were 4[xM and 
8|iM after 24 hours post-incubation compared with the control that did not have any 
treatment. Figure 4.4.4 (B) shows anti-proliferative effect of antisense oligonucleotide 
were 33% and 48% after 48 hours post-incubation in complete medium i f the antisense 
oligonucleotide concentration were 4|aM and 8|aM respectively. Figure 4.4.4 (C) shows 
anti-proliferative effect of antisense oligonucleotide were 0% and 13% after 72 hours 
post-incubation in complete medium i f the antisense oligonucleotide concentration were 
and respectively. 
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Figure 4.4.4 (A) Time-course study of antisense oligonucleotide effect on Caco-
2 cell proliferation (24 hours post-inucbation). 
5x104 cells were seeded on 24-well plate. Then oligonucleotide and Lipofectin 
complex was incubated with cells for 24 hours in serum and antibiotic free medium. 
After removing the OND/Lipofectin complex, cells were replaced with 10% serum 
complete medium and H^-thymidine incorporation assay was performed at 24 hours, 
tf-thymidine incorporation (counting/fig protein) reflected the cell proliferation. 
Briefly，l^iCi tf-thymidine was incubated with cells for 3 hours, the 12%TCA solution 
was used to precipitated protein and incorporated tf-thymidine was measured by 
scintillation counter. Data shown are representative of three duplicate means and 土SD. 
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Figure 4.4.4 (B) Time-course study of antisense oligonucleotide effect on Caco-
2 cell proliferation (48 hours post-inucbation). 
3x104 cells were seeded on 24-well plate. Then oligonucleotide and Lipofectin 
complex was incubated with cells for 24 hours in serum and antibiotic free medium. 
After removing the OND/Lipofectin complex, cells were replaced with 10% serum 
complete medium and H^-thymidine incorporation assay was performed at 48 hours, 
tf-thymidine incorporation (counting/^ig protein) reflected the cell proliferation. 
Briefly，l|iCi H^-thymidine was incubated with cells for 3 hours, the 12%TCA solution 
was used to precipitated protein and incorporated tf-thymidine was measured by 
scintillation counter. Data shown are representative of three duplicate means and 土SD. 
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Figure 4.4.4 (C) Time-course study of antisense oligonucleotide effect on Caco-
2 cell proliferation (72 hours post-incubation). 
2x104 cells were seeded on 24-well plate. Then oligonucleotide and Lipofectin 
complex was incubated with cells for 24 hours in serum and antibiotic free medium. 
After removing the OND/Lipofectin complex, cells were replaced with 10% serum 
complete medium and H^-thymidine incorporation assay was performed at 72 hours, 
tf-thymidine incorporation (counting/^g protein) reflected the cell proliferation. 
Briefly, l^iCi H^-thymidine was incubated with cells for 3 hours, the 12%TCA solution 
was used to precipitated protein and incorporated H'-thymidine was measured by 
scintillation counter. Data shown are representative of three duplicate means and 土SD. 
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4.5 The effect of antisense oligonucleotide against Glutl, 
Gluts and Gluts on cell viability of Caco-2 cells 
Effect of antisense oligonucleotide against Glutl, Glut3 and Glut5 on cytotoxicity 
of Caco-2 cells was investigated. Cells were incubated with oligonucleotides and 
Lipofectin complex for 24 hours, then further incubated in complete medium for 48 
hours. Figure 4.5 showed that when 5fiM of Glutl and Glut3 and GlutS were added to 
cells, the percentage of cell viabilities were 62%, 51% and 65% respectively. 
Antisense oligonucleotides against Glut 1 and Glut 3 were more effective in decreasing 
the cell viability comparing with antisense oligonucleotide against GlutS under the same 
concentration. 
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Figure 4.5 The effect of antisense oligonucleotide against of Glutl, Glut3 
and Gluts on Caco-2 cells. 
1x104 cells were seeded on 96-well plates. Aliquots of 0-5|iM oligonucletide and 
Lipofectin complex (w/w, 1:1) were exposured to the cells for 24 hours in serum, 
antibiotics-free medium, and then cells were further expoursed for 48 hours in complete 
medium. Cells viability was measued by MTT assay. The effect of antisense 
oligonucleotides against the start codon of Glutl, Glut3 and Glut5 were compared. The 
value for untreated control cells was set at 100%. Data shown are representative of five 
duplicate means and 土SD. 
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4.6 Analysis of ATP content in Caco-2 cells by using 
antisense oligonucleotide flanking start codon (G5 7015) 
The ATP content of Caco-2 cell after treatments of S^iM and 4|iM antisense 
oligonucleotide against GlutS was investigated. ATP content was measured by Sigma 
ATP kit and the concentration of ATP was determined by standard curve (Figure 4.6 (A)). 
Cells were incubated with 8)iM and 4[iM oligonucleotide/Lipofectin complex (w/w = 1:1) 
for 24 hours in serum free medium. Then cells were further incubated in complete 
medium for 24-72 hours. ATP content was investigated at that time. In Figure 4.6 (B), 
it was found that antisense oligonucleoitde against G5 7015 could decrease the ATP 
content at 24-72 hours post-incubation compared to that of sense control. Table 4.6 
listed the ATP content value of sense control and antisense treatment. 
4.7 Effect of G5 7015 on HepG2 cells 
The cytotoxic effects of oligonucleotides flanking start codon of the GlutS gene on 
Hep-2 cells were studied. Cells viability was measured by MTT assay. Figure 4.7 (A) 
shows that there was no difference in cell viability between the sense oligonucleotide and 
antisense oligonucleotide at concentration of 0-10|LIM. 
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24 hours 
Concentration of Antisense Sense 
oligonucleotide ()_iM) 
4 87% 106% 
8 81% 106% 
* The serum free control was set as 100% 
48 hours 
Concentration of Antisense Sense 
oligonucleotide (|iM) 
4 76% 99% 
8 95% 105% 




Concentration of Antisense Sense 
j� oligonucleotide (fiM) 
i 
t 
- 4 96% 108% 
I 8 108% 116% 
I J 
f * The serum free control was set as 100% 
I 
f Table 4.6 ATP content value of sense control and antisense treatment. 
；I 
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I Figure 4.6 Effect of antisense oligonucleotide against G5 7015 on ATP 
content of Caco-2 cel l .-
i 
I 
(A) ATP concentration was determined by standard curve using ATP assay kit which was 
obtained from Sigma Co. for determining the ATP content. (B) Cells were seeded at 6-
well plate and incubated with oligonucleotide/Lipofectin (w/w = 1:1) for 24 hours in 
I serum free medium. Then cells were post-incubated in complete medium for 24-72 
hours. Cells were trypsinized and ATP content was determined. 
(； 
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Figure 4.7 Cytotoxic effects of sense and antisense effect of different 
j regions of 15-mer oligonucleotide G57015 targeting the start 
� codon flanking on HepG-2 cells, 
f 
？I 
1x104 cells were seeded on 96-well plates. 0-10)iM of antisense oligonucleotides with 
I Lipofectin (1:1，w/w) were added to cells and allowed for 24 hours transfection in serum, 
i ‘ 
i antibiotics-free medium. Then cells were further incubated for 48 hours in complete 
S medium. The cell viability was measured by MTT assay. The value for untreated 
I 
'： control cells was set at 100%. Data shown are representative of five duplicates means 
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CHAPTER 5 
EFFECT OF ANTISENSE OLIGONUCLEOTIDES 
AGAINST GLUTS ON mRNA AND PROTEIN 
LEVELS OF GLUTS GENE 
5.1 Introduction 
1 It is believed that a true antisense mechanism results from oligonucleotide-target 
f t: 
niRNA hybrid formation, which stimulates the cleavage of mRNA at one or more sites 
near the terminus of the hybrid complex. The best way to monitor the effect of 
antisense oligonucleotides is to check the mRNA and protein levels of the target gene 
after transfection of oligonucleotide. In this chapter, RT-PCR was performed to 
determine whether the observed inhibition of GlutS (fructose transporter) expression was 
correlated with a reduction in message level. Total RNA was extracted from both 
control or oligonucleotide-treated Caco-2 cells. Glut5 specific primer was used and 
produced a single band of 581 bp. GADPH was used as a control gene to ensure the 
equal amount of RNA loading. For the protein level, Western blotting was performed 
and Gluts polyclonal antibody was used to detect the expression of GlutS protein. 
Finally，the Glut5 activity was further analysed by D-[C'^]-fructose uptake assay to 
farther prove the effect of antisense oligonucleotides against GlutS gene. 
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5.2 RT-PCR of Glut isoform in Caco-2 cells 
： RT-PCR using specific primers for Glutl, 2, 3，4, 5 was performed. As shown in 
Figure 5.2, Caco-2 cells expressed Glutl, 2，3，4 and 5. Glut 1, Glut 2，GlutS, Glut4 and 
Gluts specific primer formed a single band of 670bp, 900bp, 479bp, 1320bp，and 581bp 
repectively. 
5.3 Effect of antisense oligonucleotides against Glut 5 on 
mRNA level in Caco-2 cells 
5.3.1 Effect of oligonucleotides targeted different region of Gluts 
gene on Gluts message level 
There is no rule to predict the most effective oligonucleotide able to eliminate the 
messenger of a target gene. In order to identify effective antisense oligonucleotides 
capable of inhibiting specifically GlutS mRNA expression in Caco-2 cells, five 15-mer 
phosphorothioate oligonucleotides complementary to Glut5 were used. 5\xM of 
antisense oligonucleotide and sense control targeting different regions of GlutS mRNA 
including 5'-non-coding region, start codon, coding region and stop codon were 
incubated withr cells for 24 hours. Same amount of Lipofectin (w/w) was added to aid 
the transfection of oligonucleotide. After 48 hours post-incubation in complete medium, 
total RNA was extracted and RT-PCR was preformed. GADPH was used to confirm 
equal amount of RNA loading. The inhibition of mRNA level was studied by RT-PCR. 
Figure 5.3 shows that except G5 4615 that flanks the 5丨-non-coding region had no effect 
i — 
on the Gluts mRNA level, other oligonucleotides led to a reduction in the mRNA in 
i 
different levels. 
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• Figure 5.2 RT-PCR of Glut isoforms in Caco-2 cell. 
a 
t, 
I Specific RT-PCR amplification of mRNA of Glut 1’ 2，3，4 and 5 from Caco-2 cells was 
[ performed. The 100-bp or 250-bp DNA ladder marker was used. ！ - u 
i -
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Figure 5.3.1 Studies for the suppression of GlutS mRNA level in Caco-2 
cells after treatment of five different phosphorothioate 
oligonucleotide targeted GlutS mRNA. 
Cells were treated with 5]jM oligonucleotide and Lipofectin (w/w, 1:1) for 24 hours in 




I C h a p t e r 5 E f f e c t o f A n t i s e n s e O l i g o n u c l e o t i d e s a g a i n s t G l u t 5 o n m R N A a n d P r o t e i n l e v e l s o f G I u t 5 G e n e 
complete medium. Amplified PGR fragments were run on a 1% agarose gel and 
visualized with ethidium bromide staining. RT-PCR was performed with total RNA 
using Gluts specific primer. Antisense (lane 1) or sense control (lane 2) 
oligonucleotide treated samples were recorded. Sample on lane 3,4 was GADPH using 
as control to confirm equal amount of mRNA loading for antisense and sense treatment 
respectively. (A) G5 4615 targeted the 5'-non-coding region. (B) G5 7015 targeted 
the start codon. (C) G5 40415 targeted the coding region. (D) G5 96615 targeted 
another coding region. (E) G5 157115 targeted the stop codon. 
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I 5.3.2 Reduction in expression of mRNA level of GlutS by using 
I antisense oligonucleotides targeting start codon (G5 7015) 
I 
i G5 7015 that targeted the start codon is one of the most effective antisense 
i • 
oligonucleotide. Figure 5.3.2 shows treatment of cells with 5|iM antisense 
phosphorothioate oligonucleotide (AS) G5 7015 (flanking the AUG start codon) resulted 
i； in significant reductions in GlutS mRNA level compared with control (CTL) and sense 
1 
！• 
[ oligonucleotide (S). The GADPH mRNA was used as an internal standard for equal i 
I 
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Figure 5.3.2 Effect of G5 7015 (flanking start codon) oligonucleotides on 
Gluts mRNA expression in Caco-2 cells. 
Cells were treated with 5jaM oligonucleotide and Lipofectin (w/w, 1:1) for 24 hours in 
serum and antibiotic-free medium, then they were further incubated for 48 hours in 
complete medium. Amplified PCR fragments were run on a 1% agarose gel and 
visualized with ethidium bromide staining. (A) RT-PCR was performed with total 
RNA using Glut5 specific primer. 5)aM G5 7015 antisense oligonucleotide and 
Lipofectin (w/w, 1:1) (lane 1)，5[iM G5 7015 sense oligonucleotide and Lipofectin 
(w/w, 1:1) (lane 2)，and control cells treated with serum and antibiotic -free medium only 
(lane 3). (B) RT-PCR was performed with total RNA using GADPH specific primer as— 
control to confirm the RNA loading. 5\iM G5 7015 antisense oligonucleotide and 
Lipofectin (w/w, 1:1) (lane 4)，5|iM G5 7015 sense oligonucleotide and lipofectin (w/w, 
1:1) (lane 5)，and control cells treated with serum and antibiotic -free medium only (lane 
6). 
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5.3.3 Study of the dose and time dependence on inhibition of mRNA 
expression in G5 7015 treated CacO'2 cells 
The down-regulation of mRNA level with antisense oligonucleotide should be 
dependent on the concentration. Inhibition of mRNA function should also be 
dependent on the time course after treatment of oligonucleotides. In order to assess of 
necessary oligonucleotide concentration for inhibition of mRNA level. 4|aM and 8|J,M 
oligonucleotide and lipofectin (w/w, 1:1) were added to Caco-2 cells for 24 hours and 
further incubated for 24 hours and 48 hours. Figure 5.3.3 shows that the S^iM antisense 
oligonucleotide is more effective than antisense oligonucleotide in both 24 and 48 
hours post-incubation in complete medium in inhibiting mRNA level by G5 7015. On 
the same time, it was found that after 48 hours post-incubation, the mRNA level seems to 
be recovered 
5.3.4 Cross-Inhibition of antisense targeting glucose transporter 
isoforms 
To determine the role of a given isoform, antisense oligonucleotides must 
specifically suppress the expression the mRNA of the isoform of interest, not any other 
isoform mRNA-and unrelated mRNA. Caco-2 cells were treated with antisense 
oligonucleotide against Glut5. After 48 hours post-incubation in complete medium, 
total RNA was extracted with TRIzol. GADPH was used to confirm equal amount of 
RNA loading and Glutl, 2, 3，4 specific primer was used to examine whether antisense 
oligonucleotide against Glut5 cross-inhibited other isoforms of Glut family. Figure 
5.3.4 shows that GlutS antisense would specifically inhibit Glut5 mRNA level in Caco-2 
cells. 
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Figure 5.3.3 Study of dose and time dependence of G5 7015 on Caco-2 cells. 
Cells were treated with 4|^M or phosphorothioate oligonucleotide and lipofectin 
(w/w，1:1) for 24 hours in serum and antibiotic-free medium, then they were further 
incubated for 24 or 48 hours in complete medium. Amplified PCR fragmetns were run 
on a 1% agarose gel and visualized with ethidium bromide staining. RT-PCR was _ 
performed with total RNA using GlutS specific primer. GADPH was used as control to 
confirm equal amount of mRNA loadings. (A) 24 hours post incubation with 8|iM 
antisense-oligo (lane 1)，4|aM antisense-oligo (lane 2), S^iM sense control (lane 3), or 
4|_iM sense control (lane 4). (B) 48 hours post incubation with 8|iM antisense-oligo 
(lane 5), 4|.iM antisense-oligo (lane 6), 8jiM sense control (lane 7), or 4jiM sense control 
(lane 8). 一 
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Figure 5.3.4 Studies for cross-inhibition of antisense oligonucleotide against 
Glut 5 on other glucose transporter isoforms. 
Cells were treated with- 5|iM antisense and sense oligonucleotide (G57015) and 
lipofectin (w/w, 1:1) for 24 hours in serum and antibiotic-free medium, then further 
incubated for 48 hours in complete medium. Amplified PGR fragmetns were run on an 
P/o agarose gel and visualized with ethidium bromide staining. RT-PCR was 
performed with total RNA using Glutl, 2, 3, 4, 5 specific primers. Samples of 
antisense (lane 1) or sense control (lane 2) oligonucleotide were performed in all cases 
below. (A> Glutl isoform, (B) Glut2 isoform, (C) Glut3 isoform, (D) Glut4 isoform and 
(E) Glut 5 isoform. GADPH as control to confirm equal amount of mRNA loading for 
antisense and sense treatment respectively in (E) 
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5.4 Reduction in GlutS protein level using G5 7015 antisense 
oligonucleotide 
In order to determine that antisense oligonucleotide targeted start codon can 
suppress the expression of the protein level of Glut5, Western blotting was performed. 
Again, after 24 hours transfection of 4jj,M or S^iM of oligonucleotide in serum, 
antibiotic-free medium, then the cells were subject to 48 hours post-incubation in 
complete medium. Figure 5.4 shows that protein level suppressed 52% and 25% when 
8|iM and G5 7015 antisense oligonucleotides added respectively compare with that 
of negative control. 
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Figure 5.4 Effect of GlutS antisense oligonucleotide on GlutS protein 
expression in Caco-2 cells. 
Cells were treated with 4iiM or 8piM phosphorothioate oligonucleotide and lipofectin 
(w/w, 1:1) for 24 hours in serum and antibiotic-free medium, then the cells were further 
incubated for 48 hours in complete medium. Western blotting analysis of GlutS using 
Anti-rabbit human GlutS (1:200) polycolonal antibody was performed. The results of 
antisense- (lane 1), S^iM sense control (lane 2), negative control (lane 3) or 4jiM 
antisense (lane 4)，4)iM sense control (lane 5), negative control (lane 6) were recorded. 
Negative control (CTL) was performed by using serum free and antibiotic free medium 
only. — 
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5.5 Inhibition of Gluts activity using G57015 oligonucleotide 
As glucose transporter 5 is a fructose transporter, the activity of Glut5 was 
determined by D-[C''^]-fructose transport. Figure 5.5 (A) shows that Caco-2 cells took 
up fructose in a time-dependent manner with 15 minutes. Thus, this incubation period 
was used for further experiment. Aliquots of 0.5ml of tritium-labeled reaction mixture 
containing 0.5|j.Ci/ml D-[C^^]-fructose, ImM D-fructose in PBS were added to the cell 
and incubated for 15 minutes after antisense treatment, the reaction was terminated by 
lOOmM D-fructose. In Figure 5.5 (B I-III), it is clearly found that the D-[C'']-fmctose 
uptake are lower after antisense treatment compared with the sense control. The 
inhibition of D-[C'^]-fmctose uptake is concentration dependent. This means that 8jiM 
(150/0，44% and 33% at 24, 48 and 72 hours respectively) of antisense oligonucleotide is 
more effective in inhibiting the fructose transport (GlutS) compared with 4jaM 
oligonucleotide (9%, 31%, and 0% at 24，48 and 72 hours respectively). In comparison 
of Figure 5.5 (B III) to (B II)，the fructose transport activity recovery at 72 hours (0% 
and 33% at and S\iM respectively) post-incubation compared to those of 48 hours 
(31% and 44% at 4|liM and 8|iM respectively) post-incubation. 
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Figure 5.5 (A) Time course for fructose uptake in Caco-2 cells. 
The uptake was expressed in radioactive counting per jug of protein. The data on this 
figure is obtained from a typical experiment. The uptake of fructose was found to be 
linear between 0 to 15 minutes. 
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Figure 5.5 (B，I) Fructose transport activity in Caco-2 cells after additoion of 
antisense oligonucleotide (24 hours post-inucbation). 
2x104 cells were seeded on 24 well plate. Cell were then treated or S^iM 
phosphorothioate oligonucleotide and lipofectin (w/w, 1:1) for 24 hours in serum and 
antibiotic-free medium, and further incubated for 24 hours in complete medium. 
Aliquots of 0.5ml of tritium-labeled reaction mixture containing 0.5|iCi/ml D-[C"]-
fmctose，ImM D-fructose in PBS were added to the cell and incubated for 15 minutes 
after antisense treatment, the reaction was terminated by lOOmM D-fructose. The uptake 
was expressed in radioactive counting per i^g of protein. The data on this figure is 
obtained from a typical experiment. 
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Figure 5.5 (B,II) Fructose transport activity in Caco-2 cells after additoion of 
antisense oligonucleotide (48 hours post-inucbation). 
3x104 cells were seeded on 24 well plate. Cell were then treated 4|iM or S^lM 
phosphorothioate oligonucleotide and lipofectin (w/w, 1:1) for 24 hours in serum and 
antibiotic-free medium, and further incubated for 48 hours in complete medium. 
Aliquots of 0.5ml of tritium-labeled reaction mixture containing O.S^iCi/ml 
fmctose，ImM D-fructose in PBS were added to the cell and incubated for 15 minutes 
after antisense treatment, the reaction was terminated by lOOmM D-fructose. The uptake 
was expressed in radioactive counting per i^g of protein. The data on this figure is 
obtained from a typical experiment. 
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Figure 5.5 (B，III) Fructose transport activity in Caco-2 cells after additoion of 
antisense oligonucleotide (72 hours post-inucbation). 
2x10' cells were seeded on 24 well plate. Cell were then treated 4|uM or 8|iM 
phosphorothioate oligonucleotide and lipofectin (w/w, 1:1) for 24 hours in serum and 
antibiotic-free medium, and further incubated for 72 hours in complete medium. 
Aliquots of 0.5ml of tritium-labeled reaction mixture containing 0.5|LiCi/ml 
fmctose, ImM D-fructose in PBS were added to the cell and incubated for 15 minutes 
after antisense treatment, the reaction was terminated by lOOmM D-fructose. The uptake 
was expressed in radioactive counting per ^g of protein. The data on this figure is 
obtained from a typical experiment. 
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5.6 Inhibition of Gluts mRNA level in vivo 
The effect of G5 7015 in vivo was examined using subcutaneously implanted tumor 
xenografts in nude mice. Two weeks after implantation of IxlOVmice Caco-2 cells 
subcutaneously, antisense and sense oligonucleotides were prepared in saline solution 
and administered to tumor-bearing mice by intravenous injection at alternate days for 20 
days (ten doses) at concentration of 4mg/kg/injection in three mice. Total mRNA from 
subcutaneously growing Caco-2 tumor was extracted by TRIzol Reagent at that time. 
Tumors weighed approximately 0.5g. However, there were quite large different in the 
tumor size and weight in the same treatment group. Antisense oligonucleotide against 
G5 7015 displayed very potent inhibitory effect on Glut5 mRNA level on Caco-2 tumors 
in mice (Figure 5.6，A), whereas no effects on GlutS mRNA level were observed for the 
sense oligonucleotide (Figure 5.6, B) and the saline treatment group (Figure 5.6, C) 
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Figure 5.6 Effect of G5 7015 administration on GlutS mRNA levels in 
Caco-2 tumor cells in tumor-bearing nude mice. 
Total RNA was prepared from subcutaneously growing Caco-2 tumors in nude mice and “ 
Glut5 mRNA levels were determined by RT-PCR analysis. GADPH was used to confirm 
equal amount of mRNA loading (A) Effect of antisense oligonucleoitde G5 7015 (B) 
Effect of sense oligonucleotide of G5 7015 (C) Effect of saline administered on alternate 
day for 20 days at dose of 4mg/kg/injection, on Glut5 mRNA level in Caco-2 tumors in 
nude mice. Lane 1, mice 1; Lane 2，repeated mice 2; Lane 3, repeated mice 3. 
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CHAPTER 6 
THE POSSIBLE ROLE FOR GLUCOSE 
TRANSPORTERS IN THE MODIFICATION OF 
MULTIDRUG RESISTANCE IN TUMOR CELLS 
6.1 Introduction 
Chemotherapy is a common and effective treatment for tumors. However, after 
exposing several rounds of a given chemotherapeutic drug, tumor cells become resistant 
to a range of chemically and functionally unrelated agents. This phenomenon is named 
multidrug resistance (MDR). Resistance to multiple chemotherapeutic agents is a 
major problem that prevents the successful treatment of tumors. A major course of 
MDR is increased expression of 170-kDa p-glycoprotein (P-gp), encoded by the human 
MDRl gene. P-glycoprotein is member of the ATP-binding cassette (ABC) 
superfamily of transport protein. Figure 6.1 shows the model of P-gp and the possible 
mechanisms of action for drug efflux by P-gp (Fardel et al. 1996; Jones & George，1998; 
Johnstone et al. 2000) 
A possible role for the glucose transporter in the modulation of multidrug resistance 
was suggested. The extra-energy demand for P-glycoprotein may be met by energy-
yidding pathways. As glucose transporters (Glut 1-5) is responsible for transport of 
hexose across the membrane of mammalian cell, is hypothesized that multidrug 
resistance cells which express P-glycoprotein may be hypersensitive to glucose 
transporter inhibitors. We design experiments to prove this hypothesis in present study. 
Glucose transporter inhibitors, phloretin (PT) and cytochalasin B—(CB) can inhibit the 
glucose uptake in vitro. 2,4-Dinitrophenol (DNP) is an un-coupler of oxidative 
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phosphorylation which rapidly decreases cellular ATP level. PT, CB and DNP were 
used in this study to examine the effect of inhibition of glucose uptake and ATP level on 
doxorubicin accumulation in drug resistance cell line which expressed P-glycoprotein. 




a ^ ^ f . Diffiision 
Medium \ 
Figure 6.1 Possible Mechanism of action of drug efflux by P-glycoprotein 
(Johnstone, Ruefli, et al. 2000). 
The "Pump" model for drug transport. The three-dimensional structure of P-
glycoprotein consists of single drug pore (shown in red). Chemotherapeutic drugs 
(green) diffuse through the lipid membrane and are transported out the cell by P-gp in an 
ATP-dependent manner. 
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6.2 Materials & Methods 
6.2.1 Cell culture 
Differentiated Hepatoblastoma cell line HepG2 
HepG2 cell line was purchased form Amencan Type Culture Collection (ATCC, 
Rockville, MD, USA). Cells were maintained as monolayer culture at 37。C in a 
humidified atmosphere of 5% C〇:/95% air in RPMI 1640 medium (GIBCO-BRL) 
containing 10% fetal bovin serum (GIBCO-BRL) and 1% penicillin-streptomycin 
(lOOU/ml) (GIBCO-BRL). HepG2 cells were subcultured once a week and seeded at a 
density of 5x10^ cells per flask (75cm'). When the cells reach confluence, cells were 
washed twice with PBS. Then cells were trypsinized with 1ml trypsin-EDTA (0.25% ’ 
ImM) (GIBCO-BRL) by incubating at 37。C for 5 minutes. Complete medium was then 
added to resuspencd the cclls. 
Doxorubicin resistant HepG2 cell 
Doxorubicin resistant HcpG2 cell line, namely R-HcpG2, was developed in our 
laboratory by incubating the cclls in stepwise increased concentrations of doxorubicin. 
After HcpG2 cclls were grown to about 80% confluent, they were treated with 
doxorubicin at a higher concentration, which caused 90% of ccll death with 48 hours 
incubation. After incubating 24 hours with doxorubicin, the cells were washed several 
times by PBS. Cclls were incubatcd at the fresh medium for another 24 hours. The cclls 
were washed several iimcs again then incubatcd with fresh medium. This washing 
procedure was repeated until the cclls grew lo conflucnt. Cclls were trypsinized and 
dmdcxl into two new flasks. After the cclls grown lo 80% conflucncc, 0.2uM of 
- 9 7 -
1 
C h a p t e r 6 T h e P o s s i b l e r o l e f o r G l u c o s e T r a n s p o r t e r s i n t h e M o d i f i c a t i o n o f M u l t i d r u g R e s i s t a n c e 
i n T u m o r c e l l s 
doxorubicin was incubated with the cells. The treatments were repeated until the cell 
grew at l . l ^ M of doxorubicin. 
6.2.2 Chemicals 
RPMI-1640 without glucose and Sodium Bicarbonate 
It was purchased from Sigma and 2g of NaHCO) was supplemented to the medium. 
The pH of the medium was adjusted to pH = 7.1-7.4. Medium was filtered by 0.22|Lim 
bottle-top filter to ensure it was sterized. 
Doxorubicin 
It was purchased from Sigma and the stock solution was dissolved in PBS to Img/ml and 
stored at 4。C. This solution was passed through a 0.22|am millipore filter. 
Phloretin (PT) 
It was purchased from Sigma and the stock solution was dissolved in 100% DMSO to 
0.05M and stored at 4°C 
Cytochalasin B (CB) 
It was purchased from Sigma and the stock solution was dissolved in 100% ethanol to 
lOmg/ml and stored at 4。C. 
2,4-Dinitrophenol (DNP) 
It was purchased from Sigma and the stock solution was dissolved in distilled water to 
1.9mM and stored at 4°C 
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6.2.3 Measurement of doxorubicin uptake 
IxlO^cells were seeded onto 24 well plates，and doxorubicin was added to the cells. 
The similar procedure was performed as described in section 2.9.1 except 630nm 
longpass filter was used instead because red fluorescent signal is emitted from 
doxorubicin. 
6.3 The expression of P-glycoprotein and Doxorubicin 
resistance of R-HepG2 cells 
R-HepG2 is doxorubicin resistant cell line developed in our laboratory. Treated 
with lOjiM doxorubicin for 48 hours incubation did not cause cell death in R-HepG2, but 
in parental HepG2 the IC50 was about (Figure 6.3 (B). Doxorubicin resistance in 
R-HepG2 was caused by P-glycoprotein and it was proven by Western blotting (Figure 
6.3 (A)). 
6.4 Comparison of H^-2-deoxyglucose uptake between 
HepG2 and R-HepG2 cells 
In order to examine whether the doxorubicin resistant HepG2 cells increased in 
glucose uptake compared to parental HepG2 cells, tf-2-deoxyglucose uptake assay was 
performed. IxlO^cells were seeded on 24 well plates and incubated for 0-30 minutes. 
Figure 6.2 shows that tf-2-deoxyglucose uptake in R-HepG2 cells was about 25-40% 
higher than that of HepG2 cells in each time point. This means that resistant cells may 
need more energy than normal cells. 一 
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Figure 6.3 The P-glycoprotein expression of R-HepG2 cells. 
(A) Western blotting was performed using anti-rabbit human P-glycoprotein (1:200 
dilution) polycolonal antibody. Lane 1 was the result obtained from doxorubicin 
resistant HepG2 cell (R-HepG2) and Lane 2 was that obtained from parental HepG2 cell. 
(B) The cytotoxicity of 48 hours incubation of O-lO^iM doxorubicin in HepG2 and R-
HepG2 cells. MTT assay was used to measure the cell viability. Data shown are 
representative of five duplicate means and 土SD. 
- 1 0 0 -
C h a p t e r 6 T h e P o s s i b l e r o l e f o r G l u c o s e T r a n s p o r t e r s i n t h e M o d i f i c a t i o n o f M u l t i d r u g R e s i s t a n c e 
i n T u m o r c e l l s 
+ HepG2 - o - R-HepG2 
120 
[ 1 0 0 ^ ^ 
F S 卜 / 
r — X ^ V 一 
； 
0 ^ — 1 — 1 1 
0 10 20 30 
Time (minutes) 
Figure 6.4 Comparison of tf-2-deoxyglucose uptake in HepG2 and R-
HepG2 cells. 
Cells were seeded on 24-well plates and 2|iCi tf-2-deoxyglucose was incubated with 
0.;5ml PBS containing lOOj^ M 2-deoxy-D-glucose for 0-30 minutes. The reaction was 
-terminated by addition of lOmM 2-deoxy-D-glucose. Data shown are representative of 
three duplicate means and 士SD. 
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6.5 Quantification of Glutl and Glut3 expression by RT-PCR 
The expression of Glut 1-5 transporter isoforms in HepG2 and R-HepG2 was 
examinated by RT-PCR using specific primers. Expression of both Glutl and GlutS 
was detected in both parental HepG2 and resistant HepG2. Expression of Glut2, Glut4 
and Glut5 was not detected in both parental and resistant HepG2. Glutl specific primer 
gave a single band of 670bp in RT-PCR and Glut3 specific primer gave a single band of 
479bp after RT-PCR. Figure 6.5 (A) shows that the mRNA level of Glutl in resistant 
HepG2 cell was lower than that ofHepG2 cells, similar result obtained in the Glut3 level 
(Figure 6.5 (B)). 
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Figure 6.5 Expression of Glut 1 and Glut 3 in parental HepG2 and R-
HepG2 cell line. 
RT-PCR was performed using Glutl (23 cycle) and Glut3 (28 cycle) specific primer. 
GADPH (20 cycle) was used to confirm equal amount of RNA loading. Amplified 
PCR fragments were run on an 1% agarose gel and visualized with ethidium bromide 
staining. (A) RT-PCR was performed with Glutl specific primer, lane 1 represent 
parental HepG2 and lane 2 represents doxorubicin resistant HepG2. (B) RT-PCR was 
performed with Glut3 specific primer, lane 1 represents parental HepG2 and lane 2 
represent doxorubicin— resistant HepG2. (C) RT-PCR was performed with GADPH 
specific primer, lane 1 represents parental HepG2 and lane 2 represent doxorubicin 
resistant HepG2 
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6.6 Comparison of doxorubicin between HepG2 and R-HepG2 
cells cultured accumulation in glucose free medium 
HepG2 cells and R-HepG2 cells were loaded with 1.2|aM DOX for 24 hours in 
complete medium (RPMI 1640 with 10% serum) or medium in absence of glucose and 
serum. Flow cytometry was performed to determine the DOX accumulation in cells. 
Figure 6.6 (A) shows that the effect of glucose free medium on DOX accumulation in 
parental HepG2 cells was not significant compared with cells incubated in DOX with 
glucose. However, 3 folds on DOX uptake was found in cells culturing in glucose free 
medium comparing with that culturing with R-HepG2 culture in complete medium 
(Figure 6.6 (B)). 
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in Tumor cells 
HepG2 R-HepG2 
Negative control 3.13 5.04 
In glucose free medium with 1.2uM DOX 59.57 112.15 
In complete medium with 1.2uM DOX 52.4 30.32 
Table 6.6 The value of Mean Log DOX accumulation in cells for various 
conditions as described in Figure 6.6 
(A) 
n A ID" IO' IO� IO^  ^^O" 
(B) 
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Figure 6.6 Effects of glucose free medium on DOX uptake in HepG2 (A) 
and R-HepG2 (B) cells. 
1x105 cells were seeded on 24-well plates. 1.2nM DOX in complete medium (RPMI 
1640 with 10% serum) or glucose free medium was incubated with HepG2 and R-HepG2 
for 24 hours. The red curve represents the negative control in which cells were cultured 
in complete medium. The black curve represents cells which were cultured in 1.2|iM 
DOX in complete medium for 24 hours. The green curve represents cells which were 
cultured in 1.2|aM DOX in glucose free medium. 
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6.7 The time course of doxorubicin accumulation in R_HepG2 
cells culturing in glucose free medium 
The effect of time dependent manner of Dox accumulation in P-gp expressing R_ 
HepG2 cells was evaluated (Figure 6.7) in glucose free medium and complete medium. 
R-HepG2 cells were incubated in glucose free medium for 3, 6 and 9 hours glucose free 
medium. Then lOj^M DOX in glucose free medium were added and further incubated 
with cells for 2 hours in glucose free medium. Flow cytometry was performed to 
determine the DOX accumulation in cells. Figure 6.7 shows that pre-treatment with 
glucose free medium or complete medium, the doxorubicin accumulation increased 
in the first 6 hours of incubation and became level off after 6 hours. 
6.8 Cell viability of R_HepG2 cells after treatment of glucose 
transporter inhibitors, phloretin (PT), cytochalasin B (CB) 
and mitochondrial inhibitor, 2,4-Dinitrophenol (DNP) 
The cytoxicity of glucose transporter inhibitors, PT, CB and electron transporter 
inhibitor, DNP on the R-HepG2 cells were investigated. Cells were exposed to PT, CB 
and DNP for 24 hours and cell viability was determined by MTT assay. Figure 6.8 
shows that addition of O-lOOjaM PT (A), O-IO^M CB (B) and 0-400|iM DNP (C) gave 
more that 80% survival compared with that of control after 24 hours incubation in 37°C 
in complete medium. 
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Figure 6.7 Effect of time course of doxorubicin uptake in R-HepG2 cells 
culturing in glucose free medium. 
1x105 cells were seed on 24 well plates and were incubated in complete medium (RPMI 
1640 with 10% serum) or glucose free medium for 3，6 and 9 hours. Then cells were 
incubated in lO^iM doxorubincin for 2 hours and DOX accumulations were determined. 
The data are obtained in a typical experiment. 
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Figure 6.8 Cell viability of R-HepG2 after 24 hours exposure with glucose 
transporter inhibitors, PT (A), CB (B) and mitochondrial 
inhibitor, DNP (C). 
IxlO' cells were seeded on 96-well plate and a range PT (0-400)iM), CB (0-20|aM) and 
DNP (0-400|iM) concentration were added to cells and MTT were performed after 24 
hours incubation in 37。C. The value for untreated control cells was set at 100%. Data 
are representative of five duplicate means and 土SD. 
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6.9 Effect of glucose transporter inhibitors (PT, CB) and 
mitochondrial inhibitor (DNP) on doxorubicin 
accumulation in R-HepG2 
Range concentrations of PT (O-lOOuM), CB (0-20uM) and DNP (0-200uM) were 
loaded with l.2\xM DOX for 24 hours in complete medium (RPMI 1640 with 10% serum) 
in R-HepG2 cells. Flow cytometry was performed to determine the DOX accumulation 
in cells. Data were compared with that of control (L2|LIM DOX for 24 hours in 
complete medium). Figure 6.9 (A) shows that incubation of R-HepG2 in 0-100|iM 
Phloretin (PT), a competitive glucose transporter inhibitor, DOX accumulation increased 
by 2 fold increased. Another glucose transporter inhibitor, 20^M cytochalasin B (CB) 
also caused 2 fold increase in DOX accumulation in R-HepG2 (Figure 6.9 (B)). Figure 
6.9 (C) shows that 200|^M DNP, mitochondral inhibitor, caused 2.4 folds increased in 
DOX accumulation. The increases in doxorubicin accumulation appeared to be 
concentration dependent in CB, and DNP. But, the concentration dependent manner did 
not happen in PT, the increase of DOX accumulation was the same after additional of 10-
lOOjiM of PT「 
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conc. of PT (^iM) conc. of CB ( u M ) 纖細 c i b 1 ^ D N P \ ( u M ) 
難 雜 數 \ \ “ 、 、 4 必 V 
10 31.82 6 19.05 50 26.44 
50 33.49 10 23.95 100 29.44 
100 30.97 20 29.42 200 35.29 
Table 6.9 The value of Mean Log DOX accumulation in cells for various 




0 3 0 _ _ 
• MM 
1 25 — 一 — 
1 20 — 
o 
二 1 5 — . — 
§ 10 — —— —— — 
5 —— 一 — 
0 — — I — L . _ I — 1 I 丨 
contro l 10 50 100 
concentrat ion of PT (uM) 
- I l l -
ji 
C h a p t e r 6 T h e P o s s i b l e r o l e f o r G l u c o s e T r a n s p o r t e r s i n t h e M o d i f i c a t i o n o f M u l t i d r u g R e s i s t a n c e 




I 25 一 
— I 20 —：— 一 
3 
o 15 — 
(0 
o 10 — — 
Q 
5—— —— 
0 1 1 1 I 
control 6 10 20 
concentration of CB (uM) 
(C) 
40 
35 _ _ 
0 30 — - — — 
1 25 r - | 一 \ — 
E 3 20 — \ 一 o o 
15 _ _ , _ _ . ： \> 一 
X 、、- \ ： 
O An \ 
Q 10 
5 —、. ； \ — 
0 ~ ~ L — J ‘ ~ ~ — — 丨 ~ _ _ I _ L _ _ _ , 
control 50 100 200 
- concentration of DNP (uM) 
Figure 6.9 Effect of PT (A), CB (B) and DNP (C) on the accumulation in 
R-HepG2 cell. 
IxlO^cells were seeded on 24-well plate and a range concentration of PT (O-lOOuM), CB 
(0-20uM) and DNP (0-200uM) was loaded with DOX for 24 hours in complete 
medium (RPMI 1-^ 40 with 10% serum). The DOX accumulation in these cells were 
measured by flow cytometry. The data shown in each figures are obtained from typical 
experiments in each condition. 
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6.10 Effect of antisense oligonucleotide against Glut1 on 
doxorubicin accumulation in R-HepG2 cell 
Effect of antisense oligonucleotide against Glutl (G1 16915) on doxorubicin 
accumulation in R-HepG2 was investigated. R-HepG2 cells were seeded on 24-well 
plate and cells were treated with 0-8j^M of sense or antisense oligonucleotide in serum 
and antibiotic free medium for 24 hours, then cells were further incubated in complete 
medium for 48 hours post-incubation. The doxorubicin accumulation in R-HepG2 cells 
were determined by incubation of lOjiM doxorubicin in complete medium. Figure 6.10 
shows that and SjuM antisense oligonucleotide could increase the 26% and 20% 
respectively on DOX accumulation in R-HepG2 cells compared with that of the sense 
control. 
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Doxorubicin accumulation in R-HepG2 cells 
Concentration of Antisense Sense 
oligonucleotide 
0 125.35 1 2 5 ^ 
2 133.58 130.61 
4 154.22 121.98 
8 168.87 139.59 
Table 6.10 The value of Mean Log DOX accumulation in cells for various 
conditions as described in Figure 6.10 
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Figure 6.10 Effect of antisense oligonucleotide against Glutl on 
doxorubicin accumulation in R-HepG2 cells. 
R-HepG2 cells were seeded on 24-well plate and cells were treated with 0-8|iM of sense 
or antisense oligonucleotide in serum and antibiotic free medium for 24 hours, then cells 
were ftirther incubated in complete medium for 48 hours post-incubation. The 
- doxorubicin accumulation in R-HepG2 cells were determined by incubation of 10|iM 
doxorubicin in complete medium. 
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6.11 Analysis of ATP content and ^H-2-deoxy-D-glucose 
uptake in R-HepG2 after treatments of PT, CB and DNP 
The ATP content of R-HepG2 cells after treatments of PT (lOOuM), CB (20uM) 
and DNP (200uM) for 24 hours in complete medium (RPMI 1640 with 10% serum) were 
performed. Figure 6.10 (A) shows that incubation of R-HepG2 cells in lOOfiM 
Phloretin (PT) lOjiM cytochalasin B (CB), competitive glucose transporter inhibitors 
only caused 14% and 8% decrease in ATP concentration compared with R-HepG2 
control. However, addition of lOO i^M DNP, caused 77% decrease. I f cells were 
incubated in glucose free medium, not significant ATP concentration decrease (about 3%) 
was found. On the other hand, Figure 6.10 (B) shows that incubation of R-HepG2 in 
lOO^iM Phloretin (PT) and 100)iM DNP 64% and 10% decrease in 'H-2-deoxy-D-
glucose compared with R-HepG2 control. But, cells cultured in glucose free medium 
could cause 54% decrease in ^H-2-deoxy-D-glucose. 
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Figure 6.11 (A) Effect of PT, CB and DNP on ATP concentration in R-
HepG2 cell. (B) Effect of PT, CB and DNP on ^H-2-deoxy-D-
glucose in R-HepG2 cell. 
100|IM PT, 10|LIM CB, and 100|IM DNP was incubated for 24 hours in complete 
medium. The control (CTL) was cells incubating in complete medium (RPMI 1640 
with 10% serum). The effect of 24 hours incubation of glucose free medium (GF) were 
also determined. ATP concentration was determined by ATP kit (Sigma). IjiCi tf-2-
deoxyglucose uptake assay was determined as the procedures described before. Data 
shown are representative of three duplicate means and 土SD. 
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CHAPTER 7 
DISCUSSION 
7.1 Antisense oligonucleotide against glucose transporters 
in Caco-2 cell 
Antisense oligonucleotides have been used extensively to decrease or prevent the 
synthesis of target protein. In theory, the technique is simply to use the complement of 
target sequence of messenger RNA (mRNA) encoding the protein of interest in order to 
disrupt translation or prevent translation initiation. However, in practice, the technique 
can be challenging and requires extensive controls. In in vitro study, the 
oligonucleotides must have a good delivery system to ensure the effective 
oligonucleotide uptake into the cells. Also, the chemical modification and the length of 
oligonucleotides must be well selected. Finally, design of antisense oligonucleotide and 
control oligonucleotide (sense control or random control) is needed. The biological 
effect, including the dose response and time response of the antisense oligonucleotide 
must be studied. 
In this study, antisense oligonucleotides against glucose transporters were used as 
the therapeutic agent in Caco-2 cells. RT-PCR was used to clarify the expression of 
several types of glucose transporter isforms, i.e. Glutl, Glut2, GlutS, Glut4, and GlutS in 
this cell line. Previous studies had confirmed the expression of Glutl and GlutS in 
Caco-2 cells using peptide-specific antibodies (Harris et a l , 1992). Mahraoui et al. 
(1992) found the expression of Glut2 mRNA in these cells. However, none of them had _ 
- -
i used RT-PCR to prove the expression of glucose transporter isoforms in Caco-2 cells. 
Also whether Glut4 expression is present in Caco-2 cells was not reported by other 
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workers. 
The aim of this study is to test whether treatment of antisense oligonucleotides 
against one of the glucose transporter isoforms, Glut5, can exert anti-tumor effect in 
Caco-2 cells. GlutS was selected because Glut5 is not commonly found in normal 
tissues. However, Glutl supplies glucose for almost all the normal cells and GlutS 
provides energy for the brain. Thus, inhibition of Glutl and GlutS may cause non-
specific damage to other normal tissues i f in vivo experiment is performed later on. 
Also, the expression of Glut2 and Glut4 is quite low in Caco-2 cells. Although 
theoretically targeting Glut5 should have its advantages, we must ensure that inhibition 
of Gluts can exert anti-proliferative effect in Caco-2 cells. The results showed that 
antisense oligonucleotide against Glutl, Glut3 and GlutS could decrease the cell viability 
in Caco-2 cells by MTT assay. The percentage of survival targeting Glutl and GlutS 
were about 10% lower than that of targeting Glut5 i f the same concentration of antisense 
oligonucleotide was used. But, Glut5 was tumor specific and wil l not give toxicity to 
other normal cells that do not express GlutS. Result showed that using antisense 
oligonucleotide against Glut5 will not affect the cells viability in HepG2 cells which do 
not express GlutS gene compared with sense control. That results also indicated that 
different cell type can tolerate to the oligonucleotides treatment in different manner. 
Under the same culture conditions, oligonucleotide treatment to HepG2 cells seems to be 
more toxic than treatment of Caco-2 cell. High toxicity may due to too long 
transfection time (24 hours) or the concentration of oligonucleotide/Lipofectin complex 
! was too high for HepG2 cells. 
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7.2 Cellular uptake of oligonucleotide 
In in vitro studies, there is a good correlation between delivery of oligonucleotide 
and pharmacological effect. FITC-labeled phosphorothioate antisense oligonucleotide 
against Glut5 was used to monitor the cellular uptake of oligonucleotide into Caco-2 
cells by flow cytometry. Many parameters involved in the uptake of antisense 
oligonucleotide, including delivery system, the conditions of cell culture, and the cell 
type. In this study, cationic lipid "Lipofectin" was selected as the delivery agent. 
Published report has evaluated a series of cationic lipid structures for delivery of 
antisense oligonucleotides in which multiple ratio of cationic lipid were compared 
(Lewis et a l , 1996). Lewis et al (1996) compared a novel cationic lipid formation 
containing GS2888 and DOPE to other commercially available formulations in CV-1 cell. 
LipofectAmine (DOSPA:DOPE), LipofectAce (DDAB:DOPE) and Transfectam (DOGS) 
were less effective than Lipofectin reagent in serum free medium. Thus cationic lipid, 
Lipofectin, was selected. In this study, another commercially available transfection 
reagent FuGENE6 (non-liposomal forumulation) was used to compare with Lipofectin 
reagent. It was found that Lipofectin was more effective in enhancing phosphorothioate 
oligonucleotide compared with FuGENE6. Pervious paper (Tao et al., 1999) showed 
that FuGENE6 had higher inhibition effect in telomerase activity in HeLa cell than other 
cationic lipid DOTAP and Tfx-10, but Tao et al (1999) did not compared with Lipofectin 
reagent. 
Besides the delivery reagent, the conditions of culture may also affect the uptake of 
oligonucleotide. The percentage of confluence of cell culture and Lipofectin or 
oligonucleotide concentration resulted m varying uptake properties observed (White et 
al.T" 1999). In order to maintain reproductive results, air the experiments were 
I performed when the cells were reached 40-50% confluence according to the 
I 
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manufacturer's instruction which give the highest transfection effection. The effect of 
different culture conditions on the uptake of oligonucleotide was analyzed. Results 
showed that the FITC- labeled oligonucleotide uptake increased with the increased in 
Lipofectin and oligonucleotide concentration. It was found that the Lipofectin ratio 
increasing from 1 to 4 caused four fold increases in oligonucleotide uptake. Cationic 
lipid are thought to increase uptake of oligonucleotide by neutralizing or even reversing 
the negative charge of the oligonucleotide for more favorable interaction with negatively 
charged surfaces. Lewis et al (1996) found that a positive charge ratio of up to 24 was 
optimal in CV-1 cells using variety of liposome types including Lipofectin. However, 
White et al (1996) found the positive charge ratio of 1 was optimal for HaCaT and NHK 
(normal human keratinocytes) i f Tfx-10 was used. In my study, increasing the 
concentration of oligonucleotide uptake to 10|liM and Lipofectin ratio up to 4 did not 
reach to a plateau, thus no optimal ratio can be concluded. However, as Lipofectin 
reagent gave toxic effect to cells i f high concentration added, thus sense or random 
control must be used to ensure that Lipofectin did not give toxic effect or non-specific 
cell death. 
Oligonucleotide/cationic lipid complex is mainly internalized via endocytosis 
(Zabner et al., 1995). The mechanism for release of the nucleic acid from the 
endosome to the cytoplasm as well as the intracellular trafficking-are poorly understood. 
Recently, a model for intracellular release of oligonucleotide from cationic liposomes 
into the cytoplasm was proposed (Xu et al., 1996; Zelphati et al., 1996). After 
internalization via endocytosis, the oligonucleotide/cationic lipid complex destabilizes 
—the endosomal membrane as a result of flip-flop exchange between anionic and cationic 
lipids. Thereby, the oligonucleotide is displaced from the complex allowing the 
i . 
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accumulation of oligonucleotide in cytoplasmic granules which represent endosomes and 
lysosomes was observed after 2 hours of incubation with FITC-labeled oligonucleotide. 
The nuclear locatization of fluorescence after 24 hours indicated a significant release of 
oligonucleotide from endocytic vesicles into the cytosol and subsequent transport to the 
nucleus, suggesting that oligonucleotide may reach the target RNA. My results showed 
that within 24 hours incubation of oligonucleotide/Lipofectin complex in serum and 
antibiotic free medium, the FITC-labeled oligonucleotide uptake increased without 
levelling off. However, in absence of Lipofectin, the fluorescence became levelling off 
after 15 hours incubation. This kinetic data are consistent with these views because 
oligonucleotide with Lipofectin wil l uptake into the cell and degradated by the nuclease 
in cells rapidly. With Lipofectin (cationic lipid), 24 hours incubation was needed to 
release FITC-oligonucleotide and this treatment would not level off within 24 hours 
incubation. 
7.3 In vitro study of using antisense oligonucleotide against 
Gluts 
To design an antisense oligonucleotide that wil l be a useful tool, one must 
understand how antisense work. The most common approach is to inhibit translation of 
the protein of interest by using an antisense oligonucleotide to interact with the mRNA -
encoding that protein. The affinity of any oligonucleotide for its target nucleic acid 
sequence results from hybridization interaction, i.e. usually Waston-Crick base-paring, 
that depend on hydrogen bonding between bases. Affinity increases with length 
because of hydrogen bonding. Two antisense oligonucleotides of 15 and 21 nucleotides 
in length were designed and tested for the ability to inhibit cell growth. There is some 
conflicting evidence regarding 21 to 23-mer are less effective in inhibiting target protein 
- 1 2 1 -
Chapter 7 Discussions 
activity compared with 15-17 mer because longer oligonucleotide may offer more 
potential for non-specific contacts due to stronger intramolecular secondary structure, 
thereby reducing the antisense activity. My results showed that the cell viability of 
using 15-mer or 21-mer antisense oligonucleotide was about the same at concentration of 
1.25-10|liM. This result also indicate that 21-mer antisense oligonucleotide against 
Gluts wi l l not form intramolecular secondary structure, but the binding affinity of 15-
mer oligonucleotide is strong enough to target GlutS mRNA and inhibit the cell growth. 
Thus, 15-mer would be used instead of 21-mer oligonucleotide. 
Another consideration when designing an antisense oligonucleotide is modification 
of backbone. Some of the DNA analogs (e.g. phosphorothioates) serve as substrates for 
RNase H，whereas some backbone substitutions (e.g. 2-0-methoxy or 2'-fluoro) wil l not 
support RNase H activity. In my study, phosphorothioate oligonucleotide was selected 
because it is commonly used. 
Once the chemical modification and length of oligonucleotide and the delivery 
agent to transporter oligonucleotide enter the cells have been determined, the suitable 
sequence for antisense oligonucleotide must be selected. Not all areas of mRNA 
molecule are equally amenable to antisense hybridization and the criteria of the best 
sequence for antisense activity against target mRNA are still unknown. The reasons for 
i 
this are unclear, but probably involve mRNA secondary structure, protein-bound to the 
i 
I -
mRNA or accessibility of hybridizated mRNA. Thus, five oligonucleotide sequences 
I 
targeted different regions throughout the entire mRNA sequence of Glut 5 were designed 
i 
and evaluation of these oligonucleotide sequences in cell culture system for antisense 
I activity for both anti-proliferative effect and the ability to reduce GlutS mRNA 
expression were performed All of them were 15-mer' phosphorothioate 
I . 
\ oligonucleotides and they targeted 5'-untranslated region (G54615), start codon 
j ‘ 
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(G57015), coding regions (G540415 and G596615) and stop codon (G5157115) 
respectively. From RT-PCR, it was found that antisense oligonucleotide against 4615 
could not reduce the mRNA level of Glut5. This may due to two reasons, firstly, it may 
arrest the translation mechinery resulting from a physical block to bind of the initiation 
complex (the 40S subunit) at upstream of the initiation codon (close to the 5'-cap region). 
In this way the mRNA level wil l not decrease but still able to carry out the antisense 
effect. The second possible reason is that this region did not give antisense activity. 
Other four oligonucleotides which targeting start codon (G57015), coding regions 
(G540415 and G596615) and stop codon (G5157115) could reduce the mRNA level of 
Gliit5. This implied that these four oligonucleotides were effective in activating RNase 
H and degrading the mRNA. 
The inhibition of cell growth of these five antisense oligonucleotides was assessed 
by MTT assay. Results showed that antisense oligonucleotide against G54615 which 
targets the 5'-untranslated region did not give any anti-proliferative effect. The other 
four oligonucleotides could decrease cell viability in different manner. Among them, 
G596615 which targets the coding region was less effective in decreasing cell growth. 
Also，the sense control of G5157115 which targets the stop codon and G540415 which 
targeting coding region did cause significant inhibition of cell viability (about 40%) i f 
8|iM sense control added. In fact, i f S^iM of antisense oligonucleotide was added, the 
I 
I antisense activity (assay by MTT assay on cell viability) in descending order of five 
1 
！ 
I oligonucleotides targeting different regions is as below: start codon (G57015), coding 
regions (G540415)，stop codon (G5157115)，coding regions (G596615) and 5'-
I untranslated region (G54615). 
G57015 which targets the AUG start codon gave most effective antisense activity j - ~ 
I on inhibition of cell growth and the sense control of this oligonucleoitde did not 
.1 -
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significantly affect the cell viability (about or higher than 80% cell viability). 
Considering the antisense activity and the non-specific effect, G57015 was selected as 
the suitable antisense oligonucleotide against GlutS in Caco-2 cells. 
The first part of experiment shows that higher Lipofectin ratio would increase the 
uptake of oligonucleotide. However, when this theory was applied in MTT assay, it is 
surprising to find that high concentration of Lipofectin would cause a significant cell 
death in random or sense control. Although former study found that the Lipofectin ratio 
of 4 had the highest oligonucleotide uptake, more than 80% cell death was observed in 
random control i f 5ILIM oligonucleotide was added. Thus, in order to ensure the sense 
or random control did not give any toxic effect, Lipofectin ratio must be 1. Even i f the 
Lipofectin ratio increased to 2, the cell viability decreased to 50% in sense control 
Up to now, the conditions for using antisense oligonucleotide against GlutS in in 
vitro was well developed. 15-mer phosphorothioate oligonucleotide was mixed with 
Lipofectin to form oligonucleotide/Lipofectin complex in serum and antibiotic medium 
for 24 hours. The cells were seeded on plates at 40-50% confluence and allowed cells 
I 
I to incubate with oligonucleotide/Lipofectin complex. Then complete medium was 
I replaced and allow post-incubation for 24-72 hours. As Glut5 is fructose transporter, 
i 
Glut5 activity can be measured by C*'-Fructose uptake and mRNA level was measured 
i 
！ by RT-PCR. After 24 hours, mRNA level was reduced significantly, and the Glut5 
activity decreased 9% and 15% when and 8fiM was added respectively. After 48 
i 
I hours post-incubation, it is found that the mRNA level began to recover, but the GlutS 
activity decreased 31% and 44% when 4}iM and S^iM was added respectively. On the 
same time, the protein level was measured by Western blotting and it is found that 
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respectively, and this result matched with the Glut5 activity assay. In 72 hours post-
incubation, the Glut5 protein level began to recover, and the GlutS activity decreased 0% 
and 33% when 4[xM and S^iM was added respectively. However, the mRNA level 
cannot be digitalised because RT-PCR is semi-quantitative method, but the inhibition 
trend could be estimated. The result of the time course study (8jiM of antisense 
oligonucleotide) on proliferation of tumor cell (Caco-2), protein and mRNA level is 
outlined in Figure 7.1. In comparison, inhibition of protein expression was found to be 
delayed 24 hours after the mRNA inhibition. But the anti-proliferative effect and 
protein level show similar trend in 0-72 hours post-incubation time. 
120 r 
~ • ~ Gluts activity 
一 1 0 0 
-2 ^ * 一 • 一 proliferative effect 
g 60 
o ^ ^ 
① 4 0 - estimation of 
mRNA level by RT-
PCR 
0 ^ 1 1 
0 24 48 72 
Post-incubation hours 
Figure 7.1 Time course study (S^M antisense oligonucleotide) of G5 7015 
at 0-72 hours post-incubation time. 
Previous papers showed that antisense oligonucleotides targeting different genes can 
inhibit mRNA levels of target genes or to give anti-proliferative effect in different 
concentrations. For example, ISIS 5132 targeting c-raf-1 can inhibit proliferation of 
A549 lung carcinoma cell to 90% at concentration of 250nM (Monia, 1996). 
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However, 5[xM was needed to inhibit 93% of telomerase activity (Tao et a l , 1996). In 
this study, relatively high concentration of oligonucleotide was needed to give inhibitory 
effects on both mRNA and cell growth. The difference in concentration needed may be 
due to three reasons. Firstly, the purification method of oligonucleotide is not HPLC 
grade in my study, thus non-purified oligonucleotide may affect the activity. Secondly, 
the cell types, culture conditions or delivery agent may affect the antisense activity. 
Finally, expression of gene level wil l affect the antisense oligonucleotide concentration 
needed. 
As there are five types of glucose transporters in Caco-2 cell, inhibition of Glut 5 
may cause the cell to change its gene expression and expresses more Glut 1-4. Using 
RT-PCR, it is proven that the mRNA expression of other isoforms of glucose 
transporters did not change. Also, this result proves that antisense oligonucleotide 
against GlutS wi l l specifically inhibit GlutS gene and no cross-inhibition of other 
isoforms. 
In order to study the mechanism of anti-proliferative activity, it is suggested that 
antisense oligonucleotide against Glut5 may inhibit the energy supply to cells, therefore 
the ATP content of the cell may decrease. In ATP content assay, the ATP level 
decreased at 24-48 hours post-incubation. 
7.4 In vivo study of using antisense oligonucleotide against 
Gluts 
Due to the above reasons, testing antisense oligonucleotide in vitro before 
progressing to an in vivo experiment is needed, although this is certainly no guarantee of 
efficacy in vivo. In in vivo experiment, 100|ig/mouse was injected (i.v.) each for 2 days, 
I 
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and lasted for 20 days. The mRNA level decreased after injection of antisense 
oligonucleotide compared with sense control. However, the tumor size had a great 
difference within the same group, thus the data for tumor size and weight was not 
significant and was not shown. 
Colon cancer is a fetal disease and presently there is no effective treatment for 
patients with colon cancer who are eligible for surgical resection. Glut5 appear 
specifically in colon cancer and plays a role in the growth of tumor. Methods directed 
at eliminating the influences of Glut5, such as antisense technology, may be useful in the 
future for the treatment of patients with this aggressive cancer. 
7.5 Possible role of inhibition of glucose transport in 
reversing P-gp 
Multidrug resistance, involving cross resistant to chemotherapeutic drugs, is a big 
obstacle in the successful treatment of malignancies and is likely to contribute to 
i 
resistance in certain solid tumors. It is frequently mediated by over-expression of the P-
glycoprotein (P-gp), which flinctions as ATP-dependent drug-efflux pump. The 
development of multidrug resistance in cancer cells is accompanied by other changes 
！ 
that are potentially exploitable for their selective killing. It is often associated with an 
i increase rate of glycolysis. Much of energy demands for tumor cells are met by glucose 
transport across the plasma membrane of mammalian cell，mediated by a family of 
facilitative glucose transporters. 
In this study, doxorubicin resistant HepG2, termed R-HepG2 cells was used. It is 
cultured in 1.2|aM doxorubicin and could be tolerant for lO^M doxorubicin for 48 hours 
without any cell death. Parental HepG2 cell, however, the IC^o was about R-
- 1 2 7 -
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HepG2 expressed high level of P-glycoprotein and it was proven by Western blotting. 
Results shows that R-HepG2 cell increase glucose transport. Using ^H-2-deoxy-D-
glucose uptake assay, it was found that the glucose uptake in R-HepG2 cells increased 
25-40% compared with parental HepG2 cells. This result is consistent with previous 
papers. Martell et al. (1996) stated that 1.9 flod and 2.5 fold increases in glucose 
uptake in PC-V40 (42-fold more resistant to vincristine) and PC-V160 (42-fold more 
resistant to vincristine) respectively compared with parental MEL (murine 
erythroleuaemia) cell line were observed. As glucose transporters in tumor cells 
mediate the glucose uptake, thus it is predicted that the increase in glucose uptake is 
mediated by the overexpression of glucose transporters. However, by RT-PCR and 
Western blotting, it is found that the Glutl and Glut3 expression was lower in R-HepG2 
compared with HepG2 cell. The discordance between mRNA and protein levels and 
glucose transporter in R-HepG2 cell line may be caused by alternation in the stability of 
mRNA or the stability of protein. Bentley et al. (1997) also reported the similar results 
that Glutl were found to be reduced in a series of multidrug resistant KB cells. 
In order to find that depletion of glucose supply can reverse the activity of P-
glycoprotein, glucose free medium was incubated with R-HepG2 and parental HepG2 
cells. In R-HepG2 cells, cultured cells in glucose free medium could increase the 
doxorubicin accumulation. But in R-HepG2 cells, cultured cells in glucose free 
medium could not increase the doxorubicin accumulation. 
The possible participation of Glutl in drug resistance was previously suggested 
(Vera et al., 1991). In this study, two glucose transporter inhibitors cytochalasin B (CB) 
and phloretin (PT) and electron transporter inhibitor, DNP were used to investigate the 
increase in doxorubicin accumulation in R-HepG2 cells. Cytochalasin B has been 
demonstrated to inhibit glucose transport competitively. It may bind at or near the 
I 
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inward-facing glucose-binding site of Glutl in the region of Trp-388 to Trp-412 within 
the transmembrane segment 10-11 (Garcia et a l , 1992). Phloretin (PT) can inhibit 
glucose uptake in Caco-2 cells (Bissonnette et a l , 1996) and it can inhibit glucose in 
tumor cells in vitro and in vivo (Nelson et a l , 1993). Results show that PT can inhibit 
the glucose uptake at the same time decrease ATP concentration in cells. CB, however, 
at the concentration that did not cause significant cell death only exert mild inhibition in 
glucose uptake and ATP content in cells. DNP, which is electron transporter inhibitor, 
can significantly inhibit ATP content but not causing decrease in glucose uptake. Both 
CB, PT and DNP can increase the doxorubicin accumulation in R-HepG2 cell. Among 
them, DNP is most effective to increase doxorubicin accumulation while PT and CB 
were less effective in increasing drug accumulation. From this result, it is suggested 
that ATP inhibition may be more effective in affecting P-glycoprotein activity rather than 
that resulting from inhibition of glucose uptake. 
It is possible that multidrug resistant cells are hypersensitive to alteration in glucose 
transporter, there might be clinical potential for combinations of agents that act 
synergistically to reduce Glutl function and glucose transporter resembing in the 
preferental killing of multi-drug resistant cells. Thus antisense oligonucleotide against 
glucose transporters may give combined effect when using with anti-cancer drugs in 
killing multi-drug resistant cells. 一 
-
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